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1  Introduction 
Section 1.4 has been partly adapted from: Peng Zhang and Ernst Wagner, History of 
Polymeric Gene Delivery Systems. Topics in Current Chemistry 375 (2):26. 
1.1  Proteins as therapeutic agents 
Proteins have been evolutionarily chosen to perform specific functions in human body, 
including composing cell structures or tissue scaffolds, catalyzing various biochemical 
reactions, regulating immune responses, and transporting biomolecules in single cell 
or among organs [1]. Many diseases derive from the abnormal structures or 
undesirable expression level of proteins. Therefore, protein therapeutics present great 
potency in the treatment of various diseases [1, 2]. The advantages of protein 
therapeutics include higher functional specificity and less adverse effects over 
small-molecule drugs [1], meanwhile, protein therapeutics will not elicit permanent or 
random genetic alterations in cell genome, and have lower genetic risk, which make 
protein therapeutics a safer alternative to gene therapy [3]. Since the introduction of 
human insulin (the first recombinant protein therapeutic) in 1982, a considerable 
number of protein therapeutics have been developed and applied in disease therapy, 
such as metabolic and endocrine disorders, autoimmune diseases and malignant 
tumors [1, 2].  
Among the protein therapeutics, monoclonal antibodies came out as outstanding and 
promising representatives for the protein-based therapy since the approval of 
CD3-specific monoclonal antibody in 1986 [4, 5]. The number of approved monoclonal 
antibody in the Europe and US had dramatically increased to forty-seven by 2014 for 
the treatment of various diseases [5]. For example, bevacizumab [6-9], a humanized 
monoclonal antibody that could bind a variety of isoforms of vascular endothelial 
growth factor A (VEGFA), could be used to treat non-small-cell lung cancer and 
colorectal cancer; Adalimumab [10, 11], a human monoclonal antibody, could block 
                                                                                     Introduction 
2 
 
the interaction between tumor necrosis factor α (TNFα) and its receptors, inhibit 
inflammatory responses, and then improve rheumatoid arthritis. Especially, the recent 
approval of Pembrolizumab and Nivolumab which target the programmed cell death 
protein 1 (PD-1) and the approval of Atezolizumab which targets the programmed 
death-ligand 1 (PD-L1) by the US Food and Drug Administration (FDA) were 
considered as great successes in the cancer immunotherapy [12]. 
Besides antibody-based protein drugs, other molecular types of proteins are also 
used for therapy and diagnostic of human diseases. For instance, human albumin [13] 
has been used to treat hypoproteinaemia or nephrotic syndrome via increasing the 
osmolarity of circulating plasma and sustaining circulating blood volume; 
Interferon-γ1b (IFNγ) [14-18] could enhance antimicrobial response and inflammatory 
response, and has been applied in the treatment of osteopetrosis and granulomatous 
disease. Human follicle-stimulating hormone (FSH) [19, 20] has been used to assist 
reproduction by augmenting ovulation. Collagenase [21, 22] could be used to debride 
the necrotic tissues of wounds such as dermal ulcers or burn via digesting collagen; 
Recombinant hirudin [23, 24] could inhibit the bioactivity of thrombin, and has been 
used to treat heparin-induced thrombocytopaenia. Noninfectious surface antigen of 
hepatitis B virus [25, 26] has been widely used as vaccine for hepatitis B vaccination 
to prevent hepatitis B infection. The diagnosis of abnormal GH secretion could be 
performed with recombinant growth hormone releasing hormone (GHRH) [27, 28] 
fragment. Additionally, HIV antigens [29-31] could be used to diagnose HIV infection 
by the detection of HIV antibodies in human body.  
As mentioned above, notably, clinically applied proteins therapeutics are limited to 
those exerting bioactivities extracellularly, a large number of protein biologics which 
perform functions intracellularly have not been well developed or widely applied in 
clinical trials. Therefore, any technology to delivery specifically intact and functional 
proteins into cytosol or subcellular targets presents a tremendous potential for future 
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development of novel protein therapeutics and has great commercial significance [32]. 
In light of this, a variety of delivery technologies have been developed and optimized 
towards a safe and efficient targeted intracellular protein delivery system, such as lipid 
nanoparticles [33-35], nanocapsules [36-39], polymersomes [40, 41], nanogels [42, 
43], polymer micelles [44, 45], or coupling with cell-penetrating peptides [46-48]. 
While great effort has been made, the clinical development of intracellular protein 
delivery technologies is still in its infancy. However, with the continuous progress of 
nanobiotechnology and the development of novel intracellular protein delivery 
approaches, it is predictable that targeted intracellular protein delivery will be applied 
in the clinical treatment of human diseases with higher safety and efficacy. 
1.2  Barriers for protein delivery 
Many protein therapeutics have been successfully applied in the treatment of various 
human diseases [1, 2]. However, some challenges limit the development and 
application of potential protein therapeutics. For example, the scale up production of 
bioactive proteins with precise post-translational modifications [49] should be gained 
to meet the demand of research and marketing. Meanwhile, the development of 
commercial protein expression systems which have the capacity of large-scale 
expression of appropriately modified proteins, such as bacteria, yeast and mammalian 
cells [50-52], requires enormous time and fund. The intrinsic properties of proteins 
also make the way rocky to their therapeutic applications, such as the large sizes, 
fragile and complicated tertiary structures, varying surface charges and susceptibility 
to protease degradation [1, 53-55]. Therefore, appropriate formulation of protein 
biologics should be investigated and developed, improper formulation or modification 
of native proteins can provoke denaturation, degradation or precipitation of the protein 
molecules [55]. Regard to in vivo application, the native proteins can also be 
recognized by immune system, and then lose the bioactivities if neutralized by 
neutralizing antibodies or degraded by endolysosomal proteases after internalization  
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Scheme 1.1 Cellular barriers for intracellular protein delivery. 
by phagocytes [1, 56]. Proteins with small molecular weight could suffer from the rapid 
renal clearance from the blood circulation, and may not reach the target cells, tissues 
or organs [1, 53]. Meanwhile, unlike the hydrophobic small-molecule drugs, most of 
the native proteins cannot diffuse into the cell because of their large sizes and 
electrostatic repulsions to cell membrane [57, 58]. Another barrier for intracellular 
protein delivery is the endosomal sequestration, if the internalized proteins cannot 
escape from the endolysosomes, they will be degraded by the proteases in the 
lysosomes [36, 58]. Therefore, to maintain the bioactivity in the cytosol or reach the 
targeted subcellular organelles, such as the nucleus or the mitochondria, the 
delivered proteins must escape from the endolysosomes [59]. To cope with these 
Protein delivery
vehicles
Nucleus
Receptor
Cellular uptake
Endosomal escape
and
Cargo release
Nucleus import
Cargo proteins
Effect
Cytosol
                                                                                     Introduction 
5 
 
barriers, appropriate protein delivery platforms or strategies should be developed [54]. 
These delivery systems should appropriately formulate the proteins without affecting 
the native bioactivities of proteins, protect the protein in the blood circulation from 
dissociation from the delivery platform or inactivation by the immune system, 
decrease renal clearance to prolong the circulation half-life, meanwhile specifically 
deliver proteins to the targeted cells, tissues or organs, and then mediate precise “on 
demand” release of cargo protiens to decrease the side effects and improve efficacy 
of protein therapeutics [54, 55, 58, 60]. For the development of intracellular protein 
therapeutics, these systems must also mediate highly efficient targeted cellular 
internalization, effective endolysosomal escape to avoid being degraded by lysosomal 
proteases, timely release of proteins into the cytosol from the delivery systems 
responding to intracellular stimuli like reducing cytosolic enviroment and following 
subcellular traffic to specific subcellular sites to exert biological functions (Scheme 
1.1) [54, 58, 61]. 
1.3  Strategy for intracellular protein delivery 
Intracellularly functional proteins present a promising subclass of protein therapeutics. 
However, due to limited efficiency of delivery technologies, the therapeutic application 
of intracellularly functional proteins is still in its infancy. Immunotoxins [62, 63] have 
been investigated in the treatment of cancer patients [64]. Onconase [65] is a member 
of the ribonuclease A (RNase A) superfamily [64, 66, 67], which can degrade the 
cytosolic RNA after internalization by cancer cells and induce tumor cell killing, has 
been also evaluated in clinical trials. In general, inefficient cellular uptake and 
especially endolysosomal sequestration hinder effective protein delivery into the 
cellular cytosol. Cargo proteins are mostly trapped and degraded in the 
endolysosomes without reaching the subcellular target sites to exert subsequent 
biological actions. Therefore, novel and potential delivery technologies are highly 
demanded to deal with the encouraging future opportunities of intracellular protein 
transduction [68].  
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Among the traditional methods, electroporation and microinjection could directly 
deliver proteins into the cellular cytosol. These methods are invasive and will damage 
the cell membrane [69, 70], which make them difficult for in vivo application to 
unaccessible targeted cells, tissues or organs [61]. Cell-penetrating peptides (CPPs) 
mediated protein delivery is another most widely used method for intracellular protein 
transduction [71, 72]. CPPs can be conjugated to cargo proteins via recombinant 
protein technology or chemical post-modification [71, 72]. A variety of CPPs [73] have 
been developed and investigated for their potency in intracellular delivery of various 
protein cargoes [74, 75], such as cytokines and enzymes [61]. The main obstacle of 
CPP-mediated intracellular protein delivery is the endolysosomal sequestration of 
CPP-tagged cargo proteins [76, 77].  
Benefitting from the advances of nanotechnology, nanocarrier-based [78, 79] 
intracellular protein delivery has been considerably developed and presents several 
advantages as protein carriers [68]. First, nanocarriers can protect cargo proteins 
from denaturation or enzymatic degradation in biological environment [78, 80, 81]. 
Second, nanocarriers can prolong the half-life of proteins in blood circulation by 
increasing the size of the protein formulations and reducing renal clearance [78, 82, 
83]. Third, nanocarriers provide higher flexibility of chemical synthesis and 
modifications to improve the physical and chemical properties of the nanoparticles, 
such as the size, zeta-potential, and allow ligand modification for targeted delivery to 
specific cells, tissues or organs [84-86]. Cargo proteins can be loaded into the 
nanocarrieers by covalent conjugation, encapsulation and physical adsorption [68]. 
Among these nanocarriers, inorganic nanoparticles [68, 87], liposomes [88, 89], lipid 
nanoparticles [33-35], nanocapsules [36-39], polymersomes [40, 41], nanogels [42, 
43], polymer micelles [44, 45], or protein-based carriers [90-93], have been pursued. 
Inorganic materials, such as carbon nanotubes [87, 94], quantum dots [95], gold 
nanoparticles [96], silica nanoparticles [97, 98] or magnetic nanoparticles [99], have 
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been used as nanocarriers for intracellular protein delivery. For example, Dai and 
colleagues first used single-walled carbon nanotubes (SWNTs) to deliver streptavidin 
into a variety of cell lines [94]. They also used this platform to deliver cytochrome c 
into NIH-3T3 cells, resulting in programmed cells death [100]. However, inorganic 
materials usually have low endosomal escape, and cannot be degraded in vivo, which 
may result in cumulative toxicity. 
Liposomes are among the commonly used lipid-based nanoparticles and have been 
investigated as nanocarriers for various protein delivery [61]. For example, 
oligoarginine-modified liposomes effectively delivered β-galactosidase into the cytosol 
with a bioactive form [101]. Lysine containing cationic liposomes could mediate 
effective transduction of antibodies and albumin into cytosol through 
coveolae-mediated endocytosis [102].  
Xu et al. developed a novel protein delivery system based on the combinatorial library 
chemistry, the synthesized cationic lipid-like nanoparticles could efficiently delivery 
reversibly chemically modified proteins including RNase A and saporin into the cancer 
cells, resulting in both in vitro and in vivo antitumor activities [34]. They also developed 
combinatorial bioreducible lipid nanoparticles as the delivery platform for 
genome-deiting proteins. With this platform, they successfully delivered the 
Cas9:sgRNA complexes and Cre recombinase into human cells enabling effective 
genome editing and gene recombination with higher efficiencies than 70%. 
Meanwhile, they demonstrated effective gene recombination in mouse brain after in 
vivo Cre recombinase delivery [33]. Liu et al. used common cationic lipids to deliver 
genome-editing proteins such as Cas9:sgRNA complexes and Cre recombinase, and 
achieved efficient genome editing both in vitro and in vivo [35]. 
As mentioned above, endolysosomal sequestration is a main barrier for effective 
intracellular protein delivery, therefore, direct delivery of cargo proteins into the 
cytosol is supposed as an efficient method to conquer endosomal entrapment. Rotello 
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and colleagues developed nanoparticle-stabilized nanocapsules to deliver directly the 
green fluorescent protein and caspase-3 protein into the cytosol via a membrane 
fusion-like pathway, where the GFP presented homogeneous green fluorescence 
throughout the cells and CASP3 mediated effective cell apoptosis, validating effective 
cytosolic delivery of proteins as bioactive forms [36]. With GIPA AuNPs-stabilized 
nanocapsules, they could also directly deliver high molecular weight proteins including 
dsRed (112 kD) and β-galactosidase (464 kD) into the cytoplasma without blocking 
their biocativites, avoiding endosomal sequestration [103]. 
Yan et al. recently developed an intracellular protein transduction method using in situ 
polymerization-based encapsulation that occurs on the surface of single protein 
molecule to form single-protein nanocapsules [38]. With this platform, they could 
efficiently encapsulate various proteins into the nanocapsules, such as enhanced 
green fluorescent protein (EGFP), bovine serum albumin (BSA), horseradish 
peroxidase (HRP), caspase-3 (CAS) and superoxide dismutase (SOD). The EGFP 
nanocapsules mediated efficient cellular uptake, and a 50 h retention of intense 
fluorescence after injection into the mice. Gu et al. further improved the preparation of 
single-protein nanocapsules by encapsulating the single protein molecule with 
enzymatically degradable polymer shell, which could be degraded by proteases. They 
also used the physical adsorption instead of the covalent pre-modification on the 
surface of proteins to perform in situ polymerization. The degradable caspase-3 
nanocapsules could induce cell apoptosis in tested cancer cells [39]. 
Polymersomes provide another type of carrier for efficient intracellular protein 
delivery, which consists of amphipathic block copolymers and separate the aqueous 
interior from the outside solution through hydrophobic membranes [104-106]. Zhong 
et al. synthesized novel biodegradable chimaeric polymersomes with asymmetric poly 
(ethylene glycol)-b-poly(ε-caprolactone)-b-poly(2-(diethylamino) ethyl methacrylate) 
(PEG-PCL-PDEA) triblock copolymers using varying molecular weights of PDEA 
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blocks. Different from the outer longer PEG block (Mn= 5 kg/mol), the inside shorter 
PDEA cationic blocks (Mn= 1.1-4.1 kg/mol) are supposed to facilitate the protein 
encapsulation efficiency. Meanwhile, the hydrophobic PCL blocks are biodegradable 
and present no cytotoxicity. As a result, the polymersome with the PDEA blocks 
having a molecular weight of 2700 presented highest protein loading efficiency and 
could efficienly deliver FITC labeled cytochrome into the cytosol of RAW 264.7 cells 
[40]. In order to achieve cancer-targeting protein delivery systems, they further 
developed a Acupa modified pH-responsive chimaeric polymersomes (Acupa-CPs) 
based on Acupa-PEG-PTMBPEC-PSAC triblock copolymers, namely, 
2-[3-[5-amino-1-carboxypentyl]-ureido]-pentanedioic acid-poly(ethylene glycol)-b- 
poly(2,4,6-trimethoxybenzylidene-pentaerythritol carbonate)-b-poly (succinic acid 
carbonate). With PSMA-targeting Acupa-CPs, they efficiently deliver therapeutic 
cargo proteins including cytochrome C and granzyme B into the PSMA 
over-expressed prostate cancer cell line, LNCaP cells, resulting in specific anticancer 
effects [41]. 
Zhong et al. also developed a hyaluronic acid based nanogel platform for intracellular 
protein delivery by the combination of “tetrazole-alkene” photoclick reaction and 
inverse nanoprecipitation. This protein delivery platform showed effective growth 
inhibition of orthotopic A549 human lung tumor or MCF-7 human breast tumor after 
treatment with granzyme B or cytochrome c loaded hyaluronic acid nanogels [42, 43]. 
Kataoka et al. developed a new protein delivery method based on a core-shell 
structured charge-conversional polyionic complex (PIC) micelles with a size of 50 nm 
by electrostatic interactions between the cationic block copolymer PEG-pAsp(DET), 
namely, PEG-poly[N-(N'-(2-aminoethyl)-2-aminoethyl)aspartamide] and the 
cis-aconitic anhydride or citraconic anhydride modified cationic protein cytochrome c. 
The modifications of cytochrome c were supposed to tune the surface charge of 
proteins to decrease the pI value. The PIC micelles presented a charge-conversional 
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property because the cis-aconitic amides and citraconic amides are labile at the acidic 
endosomal pH 5.5 but keep stable at the physiological pH 7.4. The PIC micelles 
exhibited efficient endosome escape and effectively delivered the cytochrome c 
protein into the cysosol of HuH-7 cells [107].  
Supercharged proteins are a kind of naturally occurring or engineered proteins, they 
have unusually high negative or positive net theoretical charge (typically more than 1 
net charge unit per kD of protein molecular weight) [61]. Superpositively charged 
engineered GFP variants have been reported in the previous studies for the 
intracellular delivery of bioactive proteins into the mammalian cells both in vitro and in 
vivo based on their potent membrane penetrating ability [108]. Also, a variety of 
naturally occurring superpositively charged human proteins have the capacity to 
deliver bioactive proteins into the mammalian cells both in vitro and in vivo [109, 110]. 
Virus-like particles (VLPs) provide another strategy for intracellular protein delivery. 
VLPs consist of viral capsid proteins and have no virus genome, replicating ability and 
pathogenicity [92]. Cargo proteins can be encapsulated into VLPs via fusing with the 
anchoring protein [90, 91]. Reiser and colleagues efficiently encapsulated foreign 
proteins into polyomavirus-like particles and achieved effective intracellular delivery of 
GFP [111].  
1.4  Development of sequence defined oligomers for protein delivery  
Although a variety of strategies have been developed and investigated for their 
efficiency on therapeutic delivery of protein biologics. One always should keep in mind 
that the final destination of our design on macromolecule (nucleic acids or proteins) 
delivery system is for clinical application. Therefore, pharmaceutical precision of the 
protein delivery system has great significance and needs to be carefully considered. 
Inspired by the natural organisms that synthesize proteins in defined sequences 
based on the genetic sequence information stored in nucleic acids, also benefit from 
the great advances of macromolecular chemistry based on solid-phase-assisted 
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synthesis, sequence-based macromolecular synthesis can be realized via sequenced 
assembly of artificial subunits or nature-derived amino acids or lipids [112, 113]. In 
light of this, Schaffert and colleagues designed and synthesized novel artificial amino 
acid building blocks (e.g. succinoyl tetraethylene pentamine, Stp; succinoyl 
pentaethylene hexamine, Sph) [114, 115]. These artificial oligoamino acids protected 
by Fmoc and tBoc contain a few repeats of the effective aminoethylene motif that 
mediate the proton sponge effect in PEI [116, 117]. Using these artificial oligoamino 
acids, and combined with commercial Fmoc-protected amino acids or fatty acids, a 
variety of sequence defined cationic oligomers were assembled into precise 
sequences using solid-phase-assisted synthesis technology with high pharmaceutical 
precision, which are defined and reproducible in size, topology (linear, two-arm, 
three-arm, four-arm, or PEGylated two-arm architectures with targeting liagnads), 
coupling order and sites of subunits [114, 118]. All these elements play a crucial role 
in the transfection efficiency of oligomers. Therefore, in addition to pharmaceutical 
precision, synthesis of sequence defined oligomers is also significant for the 
investigation of structure–activity relationships. These sequence defined cationic 
oligomers presented efficient ability in the pDNA and siRNA delivery [114, 115]. 
Therefore, they are supposed to have the potency as delivery domains in conjugates 
of proteins or other drugs [119]. In initial work, one sequence-defined three-arm 
cationic oligomer had been conjugated with proteins by bioreducible disulfide linkage 
[120] or a pH-sensitive traceless click linker [121], and resulted in successful delivery 
of nlsEGFP or β-galactosidase into cells.  
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1.5  Aim of thesis 
Protein therapeutics [1] have gained increasing attention due to their great potential in 
the treatment of many diseases. For cancer, they may provide a higher functional 
specificity and less genetic risks than standard nontargeted chemotherapies. 
Clinically applied proteins therapeutics however are limited to those exerting 
bioactivities extracellularly, intracellularly active proteins as a therapeutic subclass still 
is in its early stage due to delivery problems. The particular crucial barriers include 
specific delivery to the targeted cells, highly efficient cellular internalization, effective 
endolysosomal escape, timely release of proteins from the delivery system and 
following subcelluar traffic to specific subcellular sites [54, 58, 61]. Among these 
barriers, especially endolysosomal entrapment hampers effective protein transduction 
into the cytosol. Cargo proteins are largely trapped and degraded in the 
endolysosomes without access to the subcellular target sites for subsequent 
biological actions. Therefore, novel delivery technologies are required to cope with 
these barriers via combing multiple functions. Precise sequence-defined oligomers 
have been designed and synthesized and contain various moieties and functions in 
our laboratory using solid-phase synthesis technology [114, 115]. In light of this, the 
thesis focuses on the development of novel nanoformulations for targeted intracellular 
protein delivery based on sequence-defined mutifunctional lipo-oligoaminoamides. 
The first aim of the thesis was to screen sequence-defined oligomers for enhanced 
targeted intracellular protein transduction and cancer therapy with effective 
endosomal escape and investigate the structure-activity relationships. For this 
purpose, 16 PEGylated two-arm or four-arm oligomers optionally containing folic acid 
for cell receptor targeting were selected and had to be evaluated for targeted 
intracellular protein transduction. Different artificial amino acid building blocks, as well 
as protonatable histidines, or oleic acids were included to enhance endosomolytic 
ability. All these oligomers had to be coupled to nlsEGFP or RNase A by disulfide 
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bonds, respectively. The disulfide linkages are supposed to be cleaved in the 
reducing cytosolic environment after endolysosomal escape [122-126]. The targeted 
intracellular transduction efficiency of nlsEGFP and RNase A via these oligomers had 
to be evaluated and compared to identify the potent transduction carrier, meanwhile, 
structure-activity relationships of these oligomers were also investigated. 
The second aim of the thesis was to screen and optimize the lipo-oligomer 
nanoformulations by formulating the most effective oligomer-protein conjugates with 
various lipids. To this end, novel nanoformulations should be developed by 
bioreversible coupling of cargo protein with the sequence defined lipo-oligomer 728 
followed by self-assembly with a variety of helper lipids (DOPS; DOPE; or linoleic 
acid), cholesterol, PEGylated lipids (DMPE-PEG2000 or DSPE-PEG2000) and 
optionally a folic acid-PEG conjugated lipid analog 1042 for targeting. Protein cargos 
RNase A or nlsEGFP were covalently coupled to lipo-oligomer 728 via disulfide 
linkages before nanoformulation. The colloidal stability of the nanoparticles in various 
conditions and targeted cytosolic delivery efficiency of cargo proteins by these 
nanoformulations should be evaluated and compared to identify the most potent 
nanoformulations. 
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2.  Materials and Methods 
2.1  Materials 
2.1.1 Chemicals and reagents 
Dichloromethane (DCM) was purchased from Bernd Kraft (Germany). Trifluoroacetic 
acid (TFA) were purchased from Acros Organics (USA). Syringe microreactors were 
obtained from Multisyntech GmbH (Witten, Germany). 2-Chlorotrityl chloride resin, 
Fmoc or Boc protected α-amino acids, N,N-diisopropylethylamine (DIPEA), peptide 
grade dimethylformamide (DMF), piperidine,benzotriazol-1-yl-oxy-tris-pyrrolidino-pho- 
sphonium hexafluorophosphate (Pybop), and 1-hydroxy-benzotriazole (HOBt) were 
purchased from Iris Biotech (Marktredwitz, Germany). Hydrazine from Merck 
(Darmstadt, Germany). 25% ammonia solution from Carl Roth (Karlsruhe, Germany). 
N10-(Trifluoroacetyl)pteroic acid was obtained from Niels Clauson-Kaas A/S (Farum, 
Denmark), Fmoc-N-amido-dPEG24-acid from Quanta Biodesign (Powell, USA). 
Cholesterol, linoleic acid (LinA), N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), 
ethylenediaminetetraacetic acid (EDTA), DL-dithiothreitol (DTT), triisopropylsilane 
(TIS), dimethyl sulfoxide (DMSO), 3,6-dioxa-1,8-octanedithiol (DODT), 
5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB), FITC, L-glutathione reduced (GSH), folic 
acid, dimethylsulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), ninhydrin, phenol, potassium cyanide (KCN), sodium hydroxide 
(NaOH), hydrochloric acid solution (HCl, 1M) were purchased from Sigma-Aldrich 
(Munich, Germany). Acetonitrile (ACN, HPLC grade) was obtained from VWR 
(Darmstadt, Germany). Deuterium oxide (D2O) from Euriso-Top (Saint-Aubin Cedex, 
France). n-hexane and methyl-tert-butyl ether (MTBE) from Brenntag (Mülheim/Ruhr, 
Germany). 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoyl- 
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DMPE- 
PEG2000), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS),1,2-distearoyl-sn- 
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glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE- 
PEG2000) were bought from Avanti Polar Lipids, Inc. HEPES from Biomol GmbH. 
BCA protein assay reagents were purchased from Thermo Scientific. Antibiotics, fetal 
bovine serum (FBS) and cell culture media were bought from Life Technologies or 
Sigma-Aldrich.  
2.1.2  Proteins 
Recombinant nlsEGFP was produced as previously reported [121]. RNase A from 
bovine pancreas were purchased from Sigma-Aldrich. 
2.1.3  Bacteria strain  
E.coli protein expression strain BL21(DE3)plysS was purchased from Novagen 
(Merck4biosciences, Darmstadt, Germany). 
2.1.4  Oligomers 
K-ε(PEG24-A)-K-α,ε[K-α,ε(Sph3-C)2]2 (706), K-ε(PEG24-FolA)-K-α,ε[K-α,ε(Sph3-C)2]2  
(707), K-ε(PEG24-E)-K-α,ε[H-K-α,ε(H-Sph)3-H-C)2]2 (712), K-ε(PEG24-FolA)-K-α,ε 
[H-K-α,ε(H-Sph)3-H-C)2]2 (713), K-ε(PEG24-E)-K-α,ε(Sph3-Y3-C)2 (714), K-ε 
(PEG24-FolA)-K-α,ε(Sph3-Y3-C)2  (715), K-ε(PEG24-E)-K-α,ε(Stp4-C-K-OA2)2 (728), 
K-ε(PEG24-FolA)-K-α,ε(Stp4-C-K-OA2)2 (729), K-ε(PEG24-E)-K-α,ε[K-α,ε(Stp3-C)2]2  
(732), K-ε(PEG24-FolA)-K-α,ε[K-α,ε(Stp3-C)2]2 (733), K-ε(PEG24-E)-K-α,ε[H-K-α,ε 
((H-Stp)3-H-C)2]2 (761), K-ε(PEG24-FolA)-K-α,ε[H-K-α,ε((H-Stp)3-H-C)2]2 (762), K-ε 
(PEG24-E)-K-α,ε[(H-Stp)4-H-Y3-C]2 (794), K-ε(PEG24-FolA)-K-α,ε[(H-Stp)4-H-Y3-C]2 
(795) were designed and provided by Dr. Dongsheng He. K-ε(PEG24-FolA)-K-α,ε(Stp4 
-C)2 (737), K-ε(PEG24-GlutA)-K-α,ε(Stp4-C)2 (937) were designed and provided by 
Philipp Klein. K-ε(PEG36-FolA)-K-α,ε(SteA)2 (1042) was designed and provided by 
Benjamin Steinborn and Dr. Ulrich Lächelt. C-(STP)3-K-α,ε[(STP)3-C]2 (386) was 
synthesized as reported before[114, 117]. 
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2.2  Methods 
2.2.1  Synthesis of the cationic building block Fmoc-Stp(Boc)3-OH 
The cationic building block Fmoc-Stp(Boc)3-OH was synthesized as reported 
before [117]. Briefly, the two primary amines of TEPA were selectively 
protected by ethyl trifluoroacetate, and then the three secondary amines of 
TEPA were protected by di-tert-butyl dicarbonate. Subsequently, the two 
primary amines were deprotected with NaOH, followed by the asymmetric 
functionalization of the two terminal primary amines with Fmoc-Osu and 
succinic anhydride, respectively. After purification with dry column 
chromatography, the cationic building block Fmoc-Stp(Boc)3-OH was obtained. 
2.2.2  Loading of 2-chlorotrityl chloride resin with Fmoc-Cys(Trt)-OH.  
2-chlorotrityl chloride resin (500 mg, chloride loading 1.55 mmol/g) was swelled 
in dry DCM for 10 min for two times. Subsequently, 0.4 eq mmol 
Fmoc-Cys(Trt)-OH and 0.9 eq mmol DIPEA were added to the resin and 
incubated at RT for 1 h. After removing the reaction solvents, the resin was 
incubated with a mixture of DCM/MeOH/DIPEA (80/15/5 v/v/v) for 10 min for 
two times at RT. After removal of the reaction mixture, the resin was washed 5 
times with DCM and about 30 mg of the resin was separated for the loading 
determination. Therefore, an exact amount of resin was treated with 1 mL 
deprotection solution (20% piperidine in DMF) for 1 h. Afterwards, the solution 
was diluted and absorption was measured at 301 nm. The loading was then 
calculated according to the equation: resin load [mmol/g] = (A*1000)/(m 
[mg]*7800*df) with df as dilution factor. The rest resin was washed 3 times with 
DMF, and then was treated 5 times for 10 minutes with 20 % piperidine in DMF. 
Reaction progress was monitored by Kaiser test. Finally, the resin was washed 
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3 times with DMF, 3 times with DCM, 3 times with n-hexane and dried under 
vacuum.  
2.2.3  Loading of 2-chlorotrityl chloride resin with Dde-Lys(Fmoc)-OH  
The loading was performed analogously to the loading of 2-chlorotrityl chloride resin 
with Fmoc-Cys(Trt)-OH. Instead of Fmoc-Cys(Trt)-OH, Dde-Lys(Fmoc)-OH was used 
as amino acid.  
2.2.4  Kaiser test 
Kaiser test was used to quantify the presence of free amines on the resin [127]. A 
small amount of DCM washed resin was transferred to an Eppendorf tube. One drop 
of each 80 % (w/v) phenol in EtOH, 5 % (w/v) ninhydrin in EtOH and 20 μM potassium 
cyanide (KCN) in pyridine were added into the Eppendorf tube. The Eppendorf tube 
was incubated for 4 min at 99 °C under shaking. For the positive Kaiser test, the 
presence of free amines was proved by blue colored resin beads and solution. For the 
negative Kaiser test, the absence of free amines was indicated by colorless resin 
beads and light yellow solution. 
2.2.5  General solid-phase synthesis process 
Solid-phase synthesis was carried out by a sequential cycle process of coupling and 
deprotection. Generally, in Fmoc-based solid-phase synthesis, the deprotected amino 
acid pre-loaded resin was incubated with a 4-fold excess of the pre-activated 
Fmoc-protected amino acids identified by the desirable sequence of oligomer at RT 
for 1 h. The pre-activation of Fmoc-protected amino acids was performed by 
incubation with an equimolar amount of HOBt, PyBOP and twice molar amount of 
DIPEA. Fmoc-deprotection was usually performed by a 10 min incubation with 20% 
piperidine in DMF for several times. Kaiser test was carried out to detect the presence 
of free amines after each coupling and deprotection step [127]. In case of unexpected 
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results (positive after coupling or negative after deprotection) of the Kaiser test, the 
last coupling or deprotection step was repeated, respectively. After full assembly of 
the oligomer sequence, the products were cleaved from the resin, purified by SEC, 
and characterized by RP-HPLC and 1HMR. 
2.2.6  Oligomer cleavage 
The completely assembled oligomers were cleaved from the resin by an incubation 
with a mixture of TFA/DODT/TIS/H2O (94:1:2.5:2.5 v/v/v) for 90 min under shaking. 
The cleavage solution was collected in a round-bottom flask and the resin was 
washed 3 times with TFA, 3 times with DCM. The combined solution was 
concentrated under reduced pressure to a final volume of approximately 1 mL and 
added dropwise to a pre-cooled 50 mL mixture of MTBE/n-hexane (1/1 v/v), then the 
precipitated crude product was obtained. After a centrifugation for 30 min at 4000 rpm 
and 4 °C, the supernatant was discarded and the precipitate was dried under a 
nitrogen stream. 
2.2.7  Synthesis of 386 
The three-arm oligomer 386 was synthesized as reported before [114]. Generally, 
2-Chlorotrityl chloride resin was preloaded with Fmoc-Cys(Trt)-OH, and then the 
cationic building block Fmoc-Stp(Boc)3-OH, Fmoc-Lys(Fmoc)-OH and 
Boc-Cys(Trt)-OH were stepwise coupled based on the desirable sequence via the 
general solid-phase synthesis process. 
2.2.8  Synthesis of 728 and 729 
2-Chlorotrityl chloride resin preloaded with Dde-Lys(Fmoc)-OH was used for the 
synthesis of 728 and 729. After Fmoc-deprotection, Fmoc-N-amido-dPEG24-OH and 
Fmoc-Glu-OtBu were stepwise coupled to the ε-amino group of the preloaded lysines. 
After another Fmoc-deprotection, the resin was separated into two parts for the further 
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synthesis of 728 and 729, respectively. For 728 synthesis, the amino group of 
Fmoc-deprotected glutamic acid was protected by di-tert-butyl dicarbonate. For 729 
synthesis, the amino group of Fmoc-deprotected glutamic acid was coupled with 
N10-(Trifluoroacetyl)pteroic acid to generate folic aicd. After finishing assembly of the 
folic acid (or glutamic acid) ligand, the Dde protection groups of α-amino groups of the 
preloaded lysines were removed by treating the resin of both 728 and 729 for 20-30 
times with 4% hydrazine in DMF (v/v), the deprotection process was monitored by 
checking absorption of the reaction solution at 290 nm. Subsequently, 
Fmoc-Lys(Fmoc)-OH, Fmoc-Stp(Boc)3-OH, Fmoc-Cys(Trt)-OH and oleic acid were 
coupled stepwise to the deprotected α-amino group of the preloaded lysine based on 
the desirable sequence via the general solid-phase synthesis process. Finally, a 
deprotection of the trifluoroacetyl-group of pteroic acid was carried out using 25% 
aqueous ammonia solution/DMF (1:1) four times for 30 min. After each deprotection 
cycle, the resin was washed with DMF. After completion of the reaction, the resin was 
washed with DMF, DCM and n-hexane and dried in vacuo. The crude product was 
purified by SEC after cleavage. 
2.2.9  Size-exclusion chromatography  
All oligomers were purified by size exclusion chromatography using an Äktapurifier 10 
platform (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) with a P-900 solvent 
pump module, a pH/C-900 conductivity module, a UV-900 UV/VIS multi-wavelength 
detector and a Frac-950 automated fractionator. Sephadex G-10 column was used for 
purification and 10 mM hydrochloric acid solution / acetonitrile (7:3) was used as 
eluent. The desirable fractions were collected, pooled and lyophilized.  
2.2.10  RP-HPLC  
The purity of the synthesized oligomers was analyzed by RP-HPLC using a Waters 
HPLC system equipped with a Waters 600E multisolvent delivery system, a Waters 
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996 PDA detector and a Waters 717plus autosampler. As indicated, the compounds 
were analyzed using a Waters Sunfire C18 or Xbridge C18 column (5 μm, 4.6 x 150 
mm) and a water/acetonitrile gradient (95:5 – 0:100) containing 0.1 % TFA. For the 
detection, the extinction at 214 nm was monitored. 
2.2.11  1H-NMR  
1H NMR spectra was performed using a Jeol JNMR-GX 400 (400 MHz) or JNMR-GX 
500 (500 MHz) without TMS as internal standard. Deuterium oxide (D2O) was used as 
solvent. All chemical shifts were calibrated to the residual proton signal of the solvent 
and are reported in ppm. Data are presented as s = singlet, d = doublet, t = triplet, m = 
multiplet. The spectra were analyzed with MestReNova (MestReLab Research).  
2.2.12  Expression and purification of nlsEGFP 
Recombinant nlsEGFP was produced as previously reported [121]. E. coli 
BL21(DE3)plysS containing nlsEGFP plasmid were grown in LB Medium (50 μg/mL 
ampicillin, 50 μg/mL chloramphenicol) at 37 °C with constant shaking to an optical 
density of 0.6-0.8 (600 nm). After cool down to room temperature, protein expression 
was induced by adding 1 mM IPTG and then incubated at 32 °C over night with 
constant shaking. Subsequently, the bacteria were harvested by centrifugation (30 
min, 4000 x g, 4 °C). The supernatant was discarded and the pellet was resuspended 
in lysis buffer (20 mM Tris, 20% sucrose, 0.2 M NaCl, 10 mM MgCl2, pH 7.5). RNase 
(10 μg/mL), DNase (30 μg/mL), lysozyme (1 mg/mL) and 1 mM PMSF were added 
into the lysis buffer. The solutions were frozen and thawed and sonicated (3 x 20 sec 
on ice, full power). The bacterial lysate was ultracentrifuged (30 min, 20000 rpm, 4 °C) 
and the supernatant was filtered using a 0.45 μm syringe filter. The proteins were 
purified by nickel chromatography using a gradient from binding buffer (50mM sodium 
hydrogenphosphate, 300 mM sodium chloride, 20 mM imidazole) to elution buffer 
(50mM sodium hydrogen phosphate, 500 mM sodium chloride, 250 mM imidazole). 
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The purified protein was dialyzed over night against PBS buffer (pH 7.4) using a 
dialysis membrane (14000 MWCO) from Carl Roth (Karlsruhe, Germany), and then 
the concentration of purified protein was quantified using BCA assay. 
2.2.13  Fluorescein-modified RNase A 
RNase A (6 mg, 0.438 μmol) was dissolved in sodium carbonate-bicarbonate buffer (2 
mL, 0.1 M pH 9.0). Then FITC (1.314 μmol) was dissolved in DMSO (5 mg/mL) and 
added to the RNase A solution. After a 2 h incubation at 25 °C, the FITC modified 
RNase A was purified by size-exclusion chromatography via a Sephadex G25 
superfine column using PBS buffer (1 mM EDTA, pH 7.4) as the mobile phase. The 
purified RNase A-FITC was concentrated by Amicon Ultra centrifugal filter units 
(Millipore; MWCO 3000 Da). Protein concentration was measured by BCA assay as 
instructions. The whole experiment process was protected from light. 
2.2.14  SPDP modification of nlsEGFP 
nlsEGFP (6 mg, 0.19 μmol) was dissolved in PBS buffer (2 mL, pH 7.4) containing 1 
mM EDTA. Then SPDP (1.14 μmol) was dissolved in DMSO (50 μL) and added to the 
nlsEGFP solution. After a 2 h incubation at 37 °C, the resulting SPDP modified 
nlsEGFP was purified by size exclusion chromatography on a Sephadex G25 
superfine column using HEPES buffer (pH 8.5, 0.3 M) as the mobile phase. Protein 
concentration was measured by BCA assay as instructions. The molar ratio of SPDP 
to nlsEGFP could be quantified by calculating the change in absorbance at 343 nm 
after reducing samples of the SPDP modified nlsEGFP with DTT using an extinction 
coefficient of 8080 M−1 cm−1 . 
2.2.15  SPDP modification of RNase A or RNase A-FITC  
RNase A (6 mg, 0.438 μmol) or RNase A-FITC (6 mg) was dissolved in PBS buffer (2 
mL, pH 7.4) containing 1 mM EDTA. Then SPDP (2.19 μmol) was dissolved in DMSO 
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(100 μL) and added to the RNase A solution or RNase A-FITC solution. After a 2 h 
incubation at 37 °C, the resulting SPDP modified proteins were purified respectively 
by size-exclusion chromatography on a Sephadex G25 superfine column using 
HEPES buffer (pH 8.6, 0.1 M) as the mobile phase. Protein concentration was 
measured by BCA assay as instructions. The molar ratio of SPDP to RNase A or 
RNase A-FITC could be quantified by calculating the change in absorbance at 343 nm 
after reducing samples of the SPDP modified RNase A with DTT using an extinction 
coefficient of 8080 M−1 cm−1. 
2.2.16  Conjugation of proteins with oligomers 
Oligoaminoamides of the oligomer library were synthesized by solid phase-assisted 
synthesis using the properly fmoc, tboc-protected artificial oligoamino acids (Stp and 
Sph) [116, 117] as reported before. [114, 116, 117, 125, 128, 129] The SPDP 
modified nlsEGFP was divided into 0.25 mg per aliquot and dissolved in HEPES 
buffer (0.5 mL, pH 8.5, 0.3 M). For SPDP modified RNase A or RNase A-FITC, the 
proteins were divided into 0.25 mg per aliquot and dissolved in HEPES buffer (0.25 
mL, pH 8.6, 0.1 M). Various oligomers dissolved in water (50 mg/mL; for 728 and 729, 
25 mg/mL) were added to the above modified protein solutions, respectively, as twice 
the molar quantity of covalently attached SPDP. This ratio was empirically found as 
optimum oligomer/cargo ratio. After a 15 min incubation at 20 °C, the formed 
conjugates were shock-frozen in liquid nitrogen and stored at −80 °C or used for 
further experiments immediately. 
For the formulation of lipo-oligomer nanoformulations, The SPDP modified RNase A 
was divided into 0.1 mg portions per aliquot and dissolved in HEPES buffer (0.2 mL, 
pH 7.4, 20 mM). The SPDP modified nlsEGFP was divided into 0.1 mg portions per 
aliquot and dissolved in HEPES buffer (0.2 mL, pH 8.5, 0.3 M). Lipo-oligomer 728 
dissolved in water (20 mg/mL) was added to the above modified protein solutions 
respectively at a twofold excess relative to covalently attached SPDP. This ratio was 
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empirically found as optimum oligomer/cargo ratio. After a 15 min incubation at 20 °C, 
the formed conjugates were immediately used for further experiments. 
2.2.17  Preparation of lipo-oligomer nanoformulations  
Lipo-oligomer nanoformulations were prepared using the lyophilization and 
rehydration method. Briefly, the aqueous solutions of protein conjugate (produced as 
described above), or corresponding free protein, or free 728 lipo-oligomer were added 
to the dry lipid mixtures with different defined molar ratios. After vortexing, the 
solutions were rapidly frozen in liquid nitrogen and lyophilized overnight. During 
lyophilization, the mixtures of protein conjugate and lipids were protected from light. 
Then, the mixtures were rehydrated with water by vortexing. The resulting solutions 
were sonicated at 40 ℃ for 5 min (ultrasonic bath USC THD/HF) and left at room 
temperature for 48 h to make sure all free thiols were oxidized. The formulated 
nanoparticles were then characterized by DLS measurement or TEM imaging. 
2.2.18  Cell culture 
Human cervix carcinoma cells (KB) or murine lymphocytic leukemia cells (L1210) 
were grown in folic acid free RPMI-1640 medium, supplemented with 10% FBS, 100 
U/mL penicillin, 100 μg/mL streptomycin and 4 mM stable glutamine. Neuro 2A cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 1 
g/L glucose, 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin and 4 mM stable 
glutamine. MCF-7 cells were grown in DMEM, supplemented with 4.5 g/L glucose, 
10% FBS, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin and 4 
mM stable glutamine. All cells were cultured at 37 °C in an incubator with 5 % CO2 
and humidified atmosphere. 
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2.2.19  Cellular association 
KB cells were seeded into 24-well plates at a density of 50 000 cells per well. After 24 
h, the 500 μL medium was replaced with fresh serum-containing medium. Then, the 
various nlsEGFP nanoparticles (final concentration 1 μM) or 729-SS-RNase A-FITC 
conjugate (final concentration 2 μM) were added into each well and incubated on ice 
for 45 min. For competition experiments with free folic acid, the KB cells were 
pretreated with 1 mM free folic acid for 30 min on ice before adding nanoparticles. 
Then, the cells were washed with 500 μL PBS, detached with trypsin/EDTA and 
diluted with PBS containing 10% FBS. After centrifugation, the cells were taken up in 
600 μL PBS containing 10% FBS. The cellular fluorescence was assayed by 
excitation of nlsEGFP or FITC at 488 nm and detection of emission at 510 nm with a 
Cyan ADP flow cytometer (Dako, Hamburg, Germany). Cells were appropriately gated 
by forward/sideward scatter and pulse width for exclusion of doublets, and 
counterstained with DAPI (4′,6-diamidino-2- phenylindole) to discriminate between 
viable and dead cells. Minimum ten thousand gated cells per sample were collected. 
Data were recorded with Summit software (Summit, Jamesville, NY). Analysis was 
done by FlowJo 7.6.5 flow cytometric analysis software. All experiments were 
performed in triplicates. 
2.2.20  Cellular internalization  
KB cells were seeded into 24-well plates at a density of 50 000 cells per well. After 24 
h, the 500 μL medium was replaced with fresh serum-containing medium. Then, the 
various nlsEGFP conjugates (final concentration 1 μM) or 729-SS-RNase A-FITC 
conjugate (final concentration 2 μM) was added into each well and incubated at 37 °C 
for 45 min or incubated at 37 °C for 24 h, followed by an incubation of 24 h in fresh 
media. Then, the cells were washed with 500 μL PBS, detached with trypsin/EDTA, 
and diluted with PBS containing 10% FBS. After centrifugation, the cells were taken 
up in 600 μL PBS (pH 4.0) to extinguish the outside fluorescence or in 600 μL PBS 
                                                                       Materials and Methods 
25 
 
containing 10% FBS. The cellular fluorescence was assayed by excitation of nlsEGFP 
or FITC at 488 nm and detection of emission at 510 nm with a Cyan ADP flow 
cytometer (Dako, Hamburg, Germany). Cells were appropriately gated by 
forward/sideward scatter and pulse width for exclusion of doublets, and 
counterstained with DAPI (4′,6-diamidino-2-phenylindole) to discriminate between 
viable and dead cells. Minimum 10 000 gated cells per sample were collected. Data 
were recorded with Summit software (Summit, Jamesville, NY). Analysis was done by 
FlowJo 7.6.5 flow cytometric analysis software. All experiments were performed in 
triplicates. 
2.2.21  Particle size and zeta potential 
Particle size and zeta potential of protein conjugates were measured by dynamic 
laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). For particle size measurement, nanoparticles were measured in 
100 μL HEPES buffer (pH 7.4, 20 mM) at a concentration of 0.25 mg/mL. Then the 
nanoparticle suspension was diluted to 800 μL for zeta potential measurement. 
2.2.22  Transmission electron microscopy (TEM)   
Formvar-carbon 300 mesh copper grids (Ted Pella Inc., Redding, USA) were 
activated by mild plasma cleaning. Afterwards, the grids were incubated with 20 µL of 
lipo-oligomer nanoformulations solution for 3 min. Excess liquid was blotted off using 
filter paper until the grid was almost dry. Before staining, the grids were washed with 5 
μL of staining solution for 5 seconds. Then, the grids were incubated with 5 μL of a 2% 
aqueous uranyl formate solution for 10 seconds, excess liquid was blotted off using 
filter paper, followed by air-drying for 20 min. Samples then were analyzed using JEM 
1011 (JEOL, Japan) at 80 kV. 
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2.2.23  Ellman’s assay  
DTNB (5,5'- dithiobis(2-nitrobenzoic acid)) stock solution (60 μL, 4 mg/mL) was 
dissolved in 2440 μL of Ellman’s buffer (0.2 M Na2HPO4 with 1 mM EDTA, pH 8.0) as 
DTNB-working solution. 30 μL of protein nanoparticles or standard cysteine solution 
were diluted in 170 μL DTNB-working solution and incubated for 15 min at 37 °C. The 
absorbance of solutions was measured at 412 nm. Concentration of the free thiol 
group was calculated via the calibration curve. 
2.2.24  Turbidity assay 
To compare the serum stability of various nanoparticles, an initial absorbance at 660 
nm was measured after 90 μL per well of the nanoparticle solutions (50 μg/mL) was 
added into the 96-well plates. The wavelength of 660 nm was selected to be 
sufficiently high to avoid absorbance by serum proteins. After this, half of the 
nanoparticles were mixed with 10 μL of FBS per well, the other half nanoparticles 
were mixed with 10 μL per well of PBS as controls. The plates were immediately 
placed at 37 ℃ for 2 h, afterwards, the absorbance at 660 nm of each well was 
measured. All readings were normalized to the above initial absorbance. All 
experiments were performed in triplicates. 
2.2.25  Calcein release assay 
RNase A nanoformulations containing calcein (0.1 M) were prepared analogously as 
described above, but with rehydrating the dry lipids mixtures with PBS (pH 7.4) 
containing 0.1 M calcein. Untrapped calcein were removed from the calcein 
containing nanoparticles by size exclusion chromatography using Sephadex G25 
column and PBS (pH 7.4) as elution buffer. After PBS (pH 7.4) or 3% triton X-100 
treatment, the change in fluorescence intensity due to calcein release from the 
nanoparticles was monitored by a multimode microplate reader (Spark 10M, Tecan, 
Switzerland) at 485 nm excitation and 535 nm emission, respectively. The 
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fluorescence intensities were normalized regarding the fluorescence intensity of the 
samples treated with PBS (pH 7.4). 
2.2.26  Erythrocyte leakage assay  
Preserved human red blood cells (obtained from LMU Clinics—Campus Grosshadern, 
Munich, Germany) were washed with PBS for several times. After centrifugation, the 
erythrocyte pellet was diluted to 5 × 107 erythrocytes per mL with PBS (buffered to the 
indicated pH). The protein conjugates or plain oligomers were diluted to 75 μL with 
above PBS, respectively, and added to a V-bottom 96-well plate (NUNC, Denmark). 
Control wells had buffer with 1% Triton X-100 for 100% lysis. Then, 75 μL erythrocyte 
suspension was added to each well, resulting in a final concentration of 1 μM 
nlsEGFP conjugates or 2 μM RNase A conjugates or 5 μM plain oligomers per well. 
The plates were incubated under constant shaking for 1 h at 37 °C. After 
centrifugation, 80 μL supernatant was analyzed for hemoglobin release at 405 nm 
with a microplate reader (Tecan Spectrafl uor Plus, Tecan, Switzerland). PBS with 
different indicated pH was used as negative control. Relative hemolysis was defined 
as hemolysis (%) = (A 405 (conjugate treated) − A 405 (PBS treated))/ (A 405 (Triton 
X treated) − (A 405 (PBS treated)) × 100.  
2.2.27  Fluorescence microscopy 
KB cells were seeded into 8 well Nunc chamber slides (Thermo Scientific, Germany) 
coated with collagen at a density of 10 000 cells per well. After 24 h, the 300 μL 
medium was replaced with fresh medium. Subsequently, the various nlsEGFP 
nanoparticles were added into each well (final concentration 1 μM) and incubated at 
37 °C for 24 h, followed by a 24 h incubation in fresh media. Then, the live cells were 
observed on a Zeiss Axiovert 200 fluorescence microscope (Jena, Germany). For 
729-SS-RNase A-FITC transfection, the same experiment was performed, but the 
final concentration was 2 μM and incubation was at 37 °C for 45 min. Then, the cells 
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were washed with 300 μL PBS and fixed with 4% paraformaldehyde, followed by 
nuclei staining with DAPI (1 μg/mL). A 63× magnification DIC oil immersion objective 
(Plan-APOCHROMAT) and appropriate filter sets for analysis of EGFP or DAPI were 
used. Data were analyzed and processed by AxioVision Rel. 4.8 software (Zeiss, 
Jena, Germany). 
2.2.28  RNase A transfection 
For the screening experiment of various RNase A conjugates, KB cells were seeded 
into 96-well plates at a density of 10 000 cells per well. After 24 h, the medium was 
replaced with 80 μL fresh medium. Subsequently, the various RNase A conjugates 
(final concentration 4 μM), RNase A-PDP (final concentration 4 μM), polymers (final 
concentration 16 μM), and mixtures of free RNase A (final concentration 4 μM) and 
polymers (final concentration 16 μM) were diluted to 20 μL with PBS, respectively, 
added to each well and incubated at 37 °C for 4 h, followed by a 44 h incubation in 
fresh media. Afterward, MTT solution (10 μL per well, 5.0 mg/mL) was added. After 
incubation for 2 h, the medium was removed and the 96-well plates were stored at 
−80 °C for at least 1 h. 100 μL DMSO per well were added to dissolve the purple 
formazan product. The optical absorbance was measured at 590 nm, with a reference 
wavelength of 630 nm, by a microplate reader (Tecan Spectrafl uor Plus, Tecan, 
Switzerland). The relative cell viability (%) related to control wells treated only with 20 
μL PBS was calculated as ([A] test/[A] control) × 100%. All experiments were 
performed in triplicates.  
For investigation of protein concentration-dependent cytotoxicity of RNase A 
conjugates on folate-receptor-positive or negative cells and the structure–activity 
relationship, KB cells, MCF-7 cells, or Neuro-2a cells were seeded into 96-well plates 
at a density of 10 000 cells per well. After 24 h, the medium was replaced with 80 μL 
fresh medium. Subsequently, the RNase A conjugates (final concentration 0.25; 0.5; 
1.0; 2.0; 4.0 μM), RNase A-PDP (final concentration 0.25; 0.5; 1.0; 2.0; 4.0 μM), 
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oligomers (final concentration 1.0; 2.0; 4.0; 8.0; 16.0 μM) were diluted to 20 μL with 
PBS, respectively, added to each well and incubated at 37 °C for 4 h, followed by a 44 
h incubation in fresh media. Afterward, cell viability was measured by the MTT assay 
as describe above. 
For lipo-oligomer nanoformulations, KB cells, Neuro 2A or MCF-7 were seeded into 
96-well plates at a density of 10 000 cells per well. After 24 h, the medium was 
replaced with 80 μL fresh medium. Subsequently, the various RNase A nanoparticles 
(final concentration 2 μM), corresponding nanoparticles without RNase A or 728, 
mixtures of nanoparticles with free RNase A (final concentration 2 μM) and RNase 
A-PDP (final concentration 2 μM), were diluted to 20 μL with PBS respectively, added 
to each well and incubated at 37 °C for 4 h in 10% FBS containing media (for serum 
stability test, 0 % FBS and 20% FBS containing media were used), followed by a 44 h 
incubation in fresh media. For competition experiments with free folic acid, the KB 
cells were pretreated with 1 mM free folic acid for 30 min on ice before adding 
nanoparticles. Afterward, cell viability was measured by the MTT assay as describe 
above. 
For investigation of protein concentration-dependent cytotoxicity of lipo-oligomer 
RNase A nanoformulations on folate receptor positive KB cells, the cells were seeded 
into 96-well plates at a density of 10 000 cells per well. After 24 h, the medium was 
replaced with 80 μL fresh medium. Subsequently, the RNase A nanoparticles (final 
concentration 0.1; 0.5; 1.0; 1.5; 2.0 μM), RNase A-PDP (final concentration 0.1; 0.5; 
1.0; 1.5; 2.0 μM) and corresponding nanoparticles without RNase A were diluted to 20 
μL with PBS respectively, added to each well and incubated at 37 °C for 4 h, followed 
by a 44 h incubation in fresh media. Afterwards, cell viability was measured by the 
MTT assay as describe above. 
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2.2.29  Cell viability assay of nlsEGFP nanoparticles 
KB cells were seeded into collagen coated 96-well plates at a density of 10 000 cells 
per well. After 24 h, the medium was replaced with 80 μL fresh medium. 
Subsequently, the nlsEGFP nanoparticles (final concentration 0.1; 0.25; 0.5; 1.0; 1.5 
μM) and nlsEGFP-PDP (final concentration 0.1; 0.25; 0.5; 1.0; 1.5 μM) were diluted 
into 20 μL with PBS, respectively, added into each well, and incubated with cells at 37 
°C for 24 h, then the medium was replaced with 100 μL fresh medium, followed by 
another 24 h incubation. Afterward, cell viability was measured by the MTT assay as 
describe above. 
2.2.30  Statistical analysis  
The statistical significance of experiments were analyzed using the Tukey test, p < 
0.05 was considered statistically significant in all analyses (95% confidence interval). 
 
                                                                                           Results 
31 
 
3.  Results 
3.1 Enhanced intracellular protein transduction by sequence defined 
tetra-oleoyl oligoaminoamides targeted for cancer therapy 
Section 3.1 has been adapted from: Peng Zhang, Dongsheng He, Philipp Michael Klein, 
Xiaowen Liu, Ruth Röder, Markus Döblinger, and Ernst Wagner, Adv. Funct. Mater. 2015, 25, 
6627–6636. 
As mentioned above, protein therapeutics [130, 131] have gained increasing attention 
due to their great potential in the treatment of many diseases. For cancer, they 
provide a higher functional specificity and less genetic risks than standard 
nontargeted chemotherapies. Clinically applied proteins therapeutics however are 
limited to those exerting bioactivities extracellularly, intracellularly active proteins as a 
therapeutic subclass still is in its early stage due to delivery problems. The particular 
crucial barriers include specific delivery to the targeted cells, highly efficient cellular 
internalization, effective endolysosomal escape, timely release of proteins from the 
delivery system and following subcelluar traffic to specific subcellular sites [54, 58, 
61]. Among these barriers, especially endolysosomal entrapment hamper effective 
protein transduction into the cytosol. Cargo proteins are largely sequestrated and 
degraded in the endolysosomes without access to the subcellular target sites for 
subsequent biological actions. Therefore, novel delivery technologies are required to 
cope with these barriers via combing multiple functions. Amongst other technologies, 
biodegradable microgel encapsulation [132], nanocapsules [133], polymer micelles 
[134], lipid-like nanoparticles [135], virus-like protein nanoparticles [136], cationic 
oligomer and polymer formulations [120, 121, 137-140] or coupling with peptide 
transduction domains [141, 142] have been pursued. Here we present bioreversible 
conjugation of the cargo protein with precise sequence-defined oligoaminoamide 
carriers as an alternative encouraging option, which have been designed and 
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syntesized and contain various moieties and functions in our laboratory using 
solid-phase synthesis technology.  
We recently synthesized such cationic oligomers based on artificial amino acid blocks 
(e.g., succinoyl tetraethylene pentamine, Stp; succinoyl pentaethylene hexamine, 
Sph) which were assembled into precise sequences, and demonstrated their efficient 
capacity in delivery of pDNA and siRNA polyplexes [114, 115]. Furthermore, receptor 
ligand and polyethylene glycol (PEG) modified oligomers were successfully generated 
for targeted nucleic acid delivery [129, 143]. This work revealed the endolysosomal 
barrier as a critical hurdle, and resulted in the design of endosomolytic domains such 
as fatty acids [114, 128] or endosomally protonatable units [129]. These units, when 
incorporated into oligomers, dramatically increased nucleic acid transfection. We 
hypothesized that the novel precise carriers might be useful also as delivery domains 
in conjugates of proteins or other drugs [119]. In initial work, one sequence-defined 
three-arm cationic oligomer had been conjugated with proteins by bioreducible 
disulfide [120] linkage for delivery of nlsEGFP or β-galactosidase into cells. In this 
work, 16 PEGylated two-arm and four-arm oligomers optionally containing folic acid 
for cell receptor targeting were selected and evaluated for targeted intracellular 
protein transduction. Different artificial amino acid building blocks, as well as 
protonatable histidines, or oleic acids were included to enhance endosomolytic ability. 
All these oligomers were coupled to nlsEGFP or RNase A by disulfide bonds, 
respectively. The disulfide linkages are supposed to be cleaved in the reducing 
cytosolic environment after endolysosomal escape [122-126]. Our new results show 
that the oleic acid modified targeted sequence-defined oligomers very potently 
transducer nlsEGFP and RNase A into the cytosol, where nlsEGFP undergoes 
efficient delivery into the nucleus, and RNase A triggers most effective killing of 
folate-receptor-positive cancer cells. 
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3.1.1  Synthesis of oligoaminoamide–protein conjugates 
From an existing library of more than 900 precise cationic oligoaminoamides, sixteen 
candidates were chosen for in-depth evaluation of intracellular protein delivery. 
Sequences and topology are shown in Table 3.1. Two representative proteins, 
nlsEGFP and RNase A, were employed to evaluate targeted intracellular protein 
delivery. The conjugation process of the various oligomers to the model proteins 
(nlsEGFP, RNase A) is shown in Figure 3.1 A. Biologically reducible N-succinimidyl 
3-(2-pyridyldithio)propionate (SPDP) linkers were utilized to covalently attach 
oligomers to nlsEGFP or RNase A through disulfide bonds. On average, every 
nlsEGFP molecule was modified with three SPDP linkers, for RNase A, two SPDP 
Table 3.1 Oligoaminoamide oligomers for protein conjugation. 
Abbreviations: FolA: folic acid; GlutA: glutaric acid; OA: oleic acid; E: glutamic acid; C: cysteine; H: 
histidine; K: branching lysine selectively modified at α and ε amines; Y: tyrosine; A: alanine; PEG24: 
polyethylene glycol containing 24 ethylene oxide monomer units.  PEGylated oligomer syntheses 
were performed by Dongsheng He and Philipp Klein (PhD students, Pharmaceutical Biotechnology, 
LMU Munich). 
Sequence (C to N Terminal) ID Topology 
K- ε (PEG24-E)-K- α,ε (Sph3-Y3-C)2 714 
2-arm 
K- ε (PEG24-FolA)-K- α,ε (Sph3-Y3-C)2 715 
K- ε (PEG24-E)-K- α,ε (Stp4-C-K-OA2)2 728 
K- ε (PEG24-FolA)-K- α,ε (Stp4-C-K-OA2)2 729 
K- ε (PEG24-GlutA)-K- α,ε (Stp4-C)2 937 
K- ε (PEG24-FolA)-K- α,ε (Stp4-C)2 737 
K- ε (PEG24-E)-K- α,ε [(H-Stp)4-H-Y3-C]2 794 
K- ε (PEG24-FolA)-K- α,ε [(H-Stp)4-H-Y3-C]2 795 
C-(STP)3-K- α,ε [(STP)3-C]2 386 3-arm 
K- ε (PEG24-A)-K- α,ε [K- α,ε (Sph3-C)2]2 706 
4-arm 
K- ε (PEG24-FolA)-K- α,ε [K- α,ε (Sph3-C)2]2 707 
K- ε (PEG24-E)-K- α,ε [H-K- α,ε (H-Sph)3-H-C)2]2 712 
K- ε (PEG24-FolA)-K- α,ε [H-K- α,ε (H-Sph)3-H-C)2]2 713 
K- ε (PEG24-E)-K- α,ε [K- α,ε (Stp3-C)2]2  732 
K- ε (PEG24-FolA)-K- α,ε [K- α,ε (Stp3-C)2]2  733 
K- ε (PEG24-E)-K- α,ε [H-K- α,ε ((H-Stp)3-H-C)2]2  761 
K- ε (PEG24-FolA)-K- α,ε [H-K- α,ε ((H-Stp)3-H-C)2]2 762 
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Figure 3.1  (A) Modification of nlsEGFP or RNase A with Stp or Sph containing 2-, 3-, or 4-arm 
oligomers (Table 3.1) via bioreducible SPDP linkers. Number of oligomers (n) covalently coupled to the 
protein: n = 3 (in average) for nlsEGFP, n = 2 (in average) for RNase A. Conjugates spontaneously 
form nanoparticles. (B) Chemical structures of oleic acid modified 2-arm oligomer 728 and 729. 
linkers were introduced per protein molecule. As shown in Figure 3.2, nlsEGFP and 
RNase A were successfully modified with representative oligomers (728, 729, 937, 
737). The treatment of nlsEGFP and RNase A conjugates with reducing GSH at 
cytosolic concentration (5 μM) generated oligomer free nlsEGFP or RNase A. The 
other oligomers also exhibited successful modification of proteins and biological 
reversibility of disulfides linkages (data not shown). In aqueous solution, the protein 
conjugates spontaneously form nanoparticles, with the sizes and surface charges  
nlsEGFP or RNase A
SPDP
2-arm, 3-arm or 4-arm OligomersOligomer-SS-nlsEGFP or Oligomer-SS-RNase A 
Stp Sph
729
728B
A
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Figure 3.2 SDS-PAGE analysis of successful modification of (A) nlsEGFP and (B) RNase A with 
representative oligomers (728, 729, 937, 737) and the bioreversibility of the disulfide bonds (5 μg 
protein). (C) Free oligomers control. Note: While nlsEGFP well separates in the SDS-PAGE from the 
oligomers (Figure 3.2 A), the small RNase A protein overlaps with the oligomers (Figure 3.2 B), with the 
FolA-PEG linked lipo-oligomer 729 (lane 4) and to some extent also 728 (lane 3). As described in the 
experimental section, oligomers are included into the conjugation step at twice molar quantity. 
Therefore it is likely that not all free lipo-oligomers will incorporate into the lipo-protein-nanoparticles by 
covalent disulfide linkage, and a small fraction remains in noncovalent form and detectable in the 
SDS-PAGE. We do not assume that this is unconjugated RNase A protein. Please note that the band 
migration like RNase A is not visible with the conjugates of lipid-free oligomers 937/737 (lanes 5 and 6) 
prepared in the analogous manner. 
determined by dynamic light scattering (DLS, see Table 3.2 for nlsEGFP; Table 3.3 for 
RNase A) strongly depending on the selected oligomer. The conjugates of RNase A  
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Table 3.2  Particle size (Z-average) and zeta potential of nlsEGFP conjugates in HEPES buffer 
determined by DLS. Variations refer to the median of three measurements of the same sample. 
 
Table 3.3  Particle size (Z-average) and zeta potential of RNase A conjugates in HEPES buffer 
determined by DLS. Variations refer to the median of three measurements of the same sample. 
nlsEGFP Conjugate Z-average (nm) Mean zeta potential (mV) Topology 
714 359.8 ± 18.2 7.69 ± 0.20 
2-arm 
715 514.4 ± 38.1 7.59 ± 0.22 
728 29.7 ± 0.5 13.07 ± 0.71 
729 36.6 ± 1.0 15.00 ± 0.70 
937 189.6 ± 17.0 3.71 ± 0.14 
737 234.9 ± 25.2 3.75 ± 0.72 
794 529.7 ± 11.0 7.49 ± 0.26 
795 637.4 ± 103.1 7.63 ± 0.29 
706 190.6 ± 0.8 14.50 ± 0.35 
4-arm 
707 512.2 ± 64.3 15.27 ± 0.50 
712 79.0 ± 9.0 16.60 ± 0.78 
713 163.1 ± 77.1 10.59 ± 1.94 
732 353.1 ± 4.3 9.25 ± 0.85 
733 970.8 ± 49.0 8.67 ± 0.76 
761 1724.3 ± 138.1 6.30 ± 0.60 
762 1190.5 ± 173.4 5.65 ± 0.55 
RNase A conjugate Z-average (nm) Mean zeta potential (mV) Topology 
714 630.6 ± 162.3 9.58 ± 0.82 
2-arm 
715 263.0 ± 85.7 13.77 ± 2.55 
728 22.5 ± 0.2 18.30 ± 1.18 
729 25.4 ± 0.7 21.27 ± 1.01 
937 256.1 ± 29.0 14.57 ± 1.04 
737 317.8 ± 13.5 17.33 ± 1.86 
794 119.2 ± 42.0 1.80 ± 1.17 
795 141.9 ± 101.8 2.91 ± 1.72 
386 182.6 ± 25.0 3.81 ± 2.57 3-arm 
706 123.4 ± 18.9 6.20 ± 0.73 
4-arm 
707 276.9 ± 110.8 10.01 ± 3.11 
712 309.8 ± 51.5 16.50 ± 1.04 
713 299.6 ± 30.5 20.53 ± 0.60 
732 180,9 ± 47,9 5.43 ± 0.76 
733 366.0 ± 63.3 11.70 ± 1.06 
761 249.1 ± 117.5 5.00 ± 1.42 
762 92.0 ± 28.1 4.86 ± 1.03 
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Figure 3.3  TEM image of 729-SS-RNAse A conjugates, performed with a Titan Themis TEM at 120 
kV. Before observation, conjugates were negatively stained with 1% pH 7.0 phosphotungstic acid 
solution. Experiment performed by Dr. Markus Döblinger (Department of Chemistry, LMU Munich).  
formed slightly smaller (23–600 nm) and more positively charged (zeta potential up to 
+22 mV) nanoparticles as compared to the nlsEGFP conjugates (30 nm to >1 μm; 
zeta up to 14 mV). Notably, only the lipo-oligomers 728 and 729 (chemical structures 
shown in Figure 3.1 B) mediated the formation of small nanoparticles with average 
sizes of 23–25 nm and +20 mV zeta potential for RNase A conjugates, and 30–36 nm 
and +14 mV zeta for nlsEGFP conjugates. The transmission electron microscopy 
(TEM) image of representative 729-SS-RNase A conjugates (Figure 3.3) showed a 
homogeneous distribution of the nanosized conjugates, with a uniform size of an 
average diameter of ≈10 nm and elliptical or worm-like shape (length >10 nm). 
3.1.2 Screening of oligomer–nlsEGFP conjugates reveals oleoyl-modified 
oligomer 729 as potent transduction carrier 
To evaluate the protein delivery efficiency and folate receptor specificity of the 
targeted oligomers, cells were transfected with nlsEGFP conjugates in standard 
serum-containing medium as described in the experimental section. Flow cytometry  
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Figure 3.4  Cellular association (A) and cellular internalization (B) of various nlsEGFP conjugates (1 
μM, oligomers indicated by ID number) after 45 min incubation with KB cells determined by flow 
cytometry. Orange: targeted oligomer conjugates; Light blue: non-targeted control oligomer conjugates; 
Red: PBS treated cell control. 
was used to quantify the fluorescence intensity. Figure 3.4 demonstrates that all the 
conjugates showed nice cellular association and internalization already after a short 
45 min incubation. The four-arm targeted oligomerconjugates (707, 713, 733, 762) did 
not display significantly better association and internalization compared with the 
conjugates of their nontargeted control oligomers. The two-arm targeted oligomer 
conjugates, 715 and 729, manifested far higher cell binding and uptake than their  
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Figure 3.5  Free folic acid competition results for 729-SS-nlsEGFP delivery. (A) Cellular association of 
729-SS-nlsEGFP conjugates (1 μM) after 45 min incubation with KB cells determined by flow 
cytometry. (B) Cellular internalization of 729-SS-nlsEGFP conjugates (1 μM) after 45 min incubation 
with KB cells determined by flow cytometry. The experiment was performed by pre-treatment of the KB 
cells with 100 μM free folic acid on ice for 30 min before adding conjugates. Orange: with free folic acid 
competition; Light blue: without free folic acid competition; Red: PBS treated cell control. 
nontargeted controls. Free folic acid competition experiment was also performed to 
further confirm the folate receptor specificity of 729-SS-nlsEGFP. The results (Figure 
3.5) revealed that free folic acid competition significantly inhibited the cellular 
association and slightly inhibited the cellular internalization of 729-SS-nlsEGFP.  
Furthermore, the fluorescence intensity was investigated after incubating the cells 
with the nlsEGFP conjugates for 24 h, followed by an additional 24 h incubation in 
fresh media (Figure 3.6). Cells treated with 712, 713, 728, 729, 794, and 795 
nlsEGFP conjugates however remained (22%–92%) enhanced green fluorescent 
protein (EGFP) fluorescence-positive, whereas the cells treated with the other 
conjugates (706, 707, 714, 715, 732, 733, 761, 762) had lost nlsEGFP fluorescence 
(<10%). Compared with 706 and 707, respectively, 712 and 713 nlsEGFP conjugates 
had a higher recovery of EGFP fluorescence. It is noteworthy that 729-SS-nlsEGFP 
showed the highest percentage of fluorescence-positive cells (92%) among all the 
conjugates.  
A B
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Figure 3.6  Representative results of cellular internalization of various nlsEGFP conjugates (1 μM, 
indicated by ID number) after 24 h incubation with KB cells, followed by an additional incubation of 24 h 
in fresh media determined by flow cytometry.  PBS: PBS treated cell control. 
Fluorescence microscopy confirmed the capacity of these oligomers to deliver 
nlsEGFP into cells, promote endolysosomal escape, and subsequent subcellular 
trafficking into the nucleus. Figure 3.7 A displays that 729-SS-nlsEGFP and 
728-SS-nlsEGFP treated cells presented homogeneous fluorescence throughout the  
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Figure 3.7 Transduction of KB cells with 729-SS-nlsEGFP (FolA-targeting) compared to 
728-SS-nlsEGFP (non-targeted) mediated protein transduction. (A) Fluorescence microscopy of the 
live KB cells treated with 1 μM 729-SS-nlsEGFP (row 1), 1 μM 728-SS-nlsEGFP (row 2), mixtures of 6 
μM 729 and 1 μM free nlsEGFP (row 3) and 1 μM nlsEGFP-PDP (row 4) for 24 h, followed by a 24 h 
incubation in fresh media. Left column: bright-field images of the treated cells. Right column: EGFP 
fluorescence of the treated cells. (B) Cellular internalization of each sample incubated with KB cells as 
described in (A). (C) Relative fluorescence intensities of cells treated with each sample as described in 
(A). The intensities were normalized regarding to the mean fluorescence intensity of the cells treated 
with nlsEGFP-PDP. ***p < 0.001; ns: no significant difference. Data are shown as mean ± SD (n=3). 
Scale bar = 20 μm. 
cells for 24 h after an incubation time of 24 h. However, cells treated with the other 
conjugates showed no fluorescence or just punctate fluorescence under the 
fluorescence microscope (data not shown). Moreover, nlsEGFP was found imported 
into the cell nuclei. In contrast, SPDP modified nlsEGFP and the mixture of 729 and 
free nlsEGFP without covalent attachment had very low efficiency to enter the treated 
cells (not detectable by fluorescence microscopy). More EGFP positive cells were  
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Table 3.4  Summary of the intracellular nlsEGFP delivery efficacy of various targeted nlsEGFP 
conjugates (indicated by oligomer ID number) 
a)+ : positive; b)- : negative 
observed in the fluorescence microscope images of 729-SS-nlsEGFP treated than 
728-SS-nlsEGFP treated cells. This was confirmed by flow cytometry. Cells treated
with SPDP modified nlsEGFP present almost the same fluorescence background 
intensity as phosphate buffered saline (PBS) treated cells (Figure 3.7 B). Cells 
incubated with a mixture of 729 and free nlsEGFP display only slightly higher 
fluorescence. Importantly, 729-SS-nlsEGFP treated cells displayed a significantly 
higher mean fluorescence intensity, sixfold higher than that of cells treated with 
nontargeted 728-SS-nlsEGFP, and tenfold higher than that of cells treated with the 
mixture of 729 and free nlsEGFP (Figure 3.7 C). In conclusion, it is noteworthy that 
729-SS-nlsEGFP is the only conjugate presenting nice cellular association, cellular 
internalization, folate receptor specificity, long-term (48 h) survival of nlsEGFP activity, 
and subcellular nuclear import among all the targeted oligomers (Table 3.4). 
3.1.3 Folate-PEG-oleoyl containing two-arm oligomer 729-SS-RNase A 
conjugate triggers potent KB carcinoma cell killing 
To further compare their protein delivery efficiency, oligomers were conjugated with 
RNase A as therapeutic cargo protein at a molar ratio of 4:1. This oligomer/cargo 
protein ratio was empirically found as most effective. Successful delivery of RNase A  
Conjugates 
(Oligomer-SS-nlsEGFP) 
Cellular 
association 
Cellular 
internalization 
Target 
specificity 
EGFP positive 
cells (48h, %) 
Nuclear 
import 
707 + + - 10 - 
713 + + - 58 - 
715 + + + 6 - 
729 + + + 92 + 
733 + + - 2 - 
762 + + - 7 - 
795 + + - 22 - 
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Figure 3.8  A) Evaluation of RNase A transfection efficiency with various RNase A conjugates on KB 
cells presented as % cell metabolic activity of control cells (MTT assay). Cells were incubated with the 
indicated agents under standard culture conditions for 4 h, followed by a 44 h incubation with fresh 
media. Black: oligomer control (16 μM); deep grey: mixtures of oligomer (16 μM) and free RNase A (4 
μM); grey: RNase A conjugates (4 μM); white: RNase A-PDP (4 μM). B) Protein 
concentration-dependent cytotoxicity of 729 mediated RNase A transfection on folate receptor positive 
KB cells in comparison to folate receptor negative cells (MCF-7 and Neuro 2A). *: compared with 
oligomer; &: compare with oligomer/RNase A. **p < 0.01, ***p < 0.001, &&p < 0.01, &&&p < 0.001. Data 
are shown as mean ± SD (n=3). 
into the cytosol was expected to elicit degradation of cytosolic RNA, thereby inducing 
cell killing. KB cells were treated with the various oligomers, the corresponding 
oligomer/RNase A noncovalent mixtures as controls, or the oligomer–RNase A 
conjugates, and the metabolic cell activity after 48 h was determined using an  
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Figure 3.9  Evaluation of RNase A transfection efficiency with various non-targeted RNase A 
conjugates on KB cells by a cell metabolic activity assay (MTT assay). Black: oligomer control (16 μM); 
Deep grey: mixtures of oligomer (16 μM) and free RNase A (4 μM); Grey: RNase A conjugates (4 μM); 
White: RNase A-PDP (4 μM). *: compared with oligomer; &: compare with oligomer/RNase A. *p < 0.05, 
**p < 0.01, ***p < 0.001, &&p < 0.01, &&&p < 0.001. Data are shown as mean ± SD (n=3). 
dimethylthiazolyldiphenyltetrazolium bromide (MTT) assay (Figure 3.8 A). Cells 
treated with oligomers only showed no or only low (up to 25%) reduction in metabolic 
activity. The corresponding dose of SPDP linker modified RNase A did also not result 
in any detectable change of cell viability. Unmodified RNase A was also nontoxic 
(data not shown). In contrast, the RNase A conjugates formed with various oligomers 
exhibited cytotoxicity. Five targeted oligomers (707, 713, 729, 733, 795) and their 
nontargeted control oligomers (706, 712, 728, 732, 794 in Figure 3.9) could 
successfully deliver RNase A into tumor cells and reduce their viability. The three-arm 
oligomer 386, previously reported as carrier for nlsEGFP delivery, could transduce 
RNase A into cells resulting in moderate (40%) reduction of cell viability. Cells treated 
with the mixtures of free RNase A and oligomers also presented appreciable reduction 
of metabolic activity. The covalent conjugates, however, always displayed a far higher 
cytotoxicity than the mixtures. Consistent with the nlsEGFP transfection results, the 
RNase A conjugates of histidinylated oligomers 712 and 713 showed higher 
cytotoxicity than those of the histidine lacking analogs 706 and 707, respectively.  
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Figure 3.10  Transduction of KB cells with 729-SS-RNase A-FITC. (A) Fluorescence microscopy of 
the KB cells treated with 2 μM RNase A-FITC-PDP (row 1), or 2 μM 729-SS-RNase A-FITC (row 2) for 
45 min short incubation. (B) Cellular association and (C) cellular internalization after 45 min incubation 
with KB cells as determined by flow cytometry. Scale bar = 20 μm. 
Among all the tested conjugates, 729-SS-RNase A (Figure 3.8 A) and its nontargeted 
728 analog (Figure 3.9) mediated the by far highest cytotoxicity, decreasing the 
viability of KB cells down to 5%, whereas the toxicity of the free oligomer was 
negligible. Based on the promising RNase A delivery efficiency, 729-SS-RNase A was 
evaluated in more detail. Figure 3.8 B presents the protein dose dependence of 
cytotoxicity. Interestingly, no significant decrease in cell viability was observed in 
folate-receptor-negative cells (MCF-7 and Neuro-2a) after incubation with 
729-SS-RNase A conjugate at the same concentrations.  
The cellular internalization and intracellular distribution of 729-SS-RNase A in KB cells 
was also investigated using fluorescein isothiocyanate (FITC) labeled RNase A to 
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obtain 729-SS-RNase A-FITC conjugates. Fluorescence microscopy (Figure 3.10 A)     
showed that free RNase A-FITC-PDP could not efficiently enter cells, as evidenced by 
lack of green fluorescence. In contrast, for 729-SS-RNase A-FITC treated cells, 
already after a relatively short 45 min incubation, a remarkable cellular uptake of 
729-SS-RNase A-FITC and intracellular accumulation in endosomes was visible as 
green punctuate fluorescence. The different cell association and internalization 
efficiencies of 729-SS-RNase A-FITC and free RNase A-FITC-PDP were also 
confirmed and quantified by flow cytometry evaluation (Figure 3.10 B,C), revealing 
again that 729 is a potent nanocarrier for protein delivery. 
3.1.4 The key role of oleic acids in oligomer 729—facilitating enhanced 
cytosolic entry via lipid membrane destabilization and subsequent cell killing 
by RNase A 
The former results clearly demonstrate that 729 outperformed other oligomers with 
endosomal escape function, such as the four-arm oligomer comprising Sph and 
histidines, in protein delivery. We conclude that the oleic acids as the endosomolytic 
unit in 729 play a crucial role in the enhanced intracellular protein delivery. Therefore, 
based on this hypothesis, control oligomers (937, 737) with the same sequence,  
 
Figure 3.11  Cellular association of nlsEGFP conjugates (1 μM) formed with 729 or 737 (analog 
without oleic acid modification) after 45 min incubation with KB cells determined by flow cytometry. 
Red: PBS treated cell control. 
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Figure 3.12  Structure-activity relationship of 729 enhanced intracellular protein delivery. (A) Cellular 
internalization of 1 μM 729 (oleic acid modified) or 737 (lacking oleic acids) targeted nlsEGFP 
conjugates after 45 min incubation with KB cells as determined by flow cytometry. (B) Fluorescence 
microscopy of live KB cells treated with 1 μM 729-SS-nlsEGFP (row 1) or 1 μM 737-SS-nlsEGFP (row 
2) for 24 h, followed by an incubation of 24 h in fresh media. Left column: bright-field images of the 
treated cells. Right column: EGFP fluorescence of the treated cells. (C) Relative fluorescence 
intensities per cell after in total 48 h after treatment as described in (B). The intensities were normalized 
regarding to the mean fluorescence intensity of cells treated with 737-SS-nlsEGFP. (D) Evaluation of 
RNase A transduction with 729 or 737 RNase A conjugates on KB cells by using a cell metabolic 
activity (MTT) assay. (E) Lytic activity of 729 or 737 nlsEGFP conjugates (1 μM) at physiological pH 7.4 
and early endosomal pH 6.5 in an erythrocyte leakage assay. (F) Lytic activity of 729 or 737 RNase A 
conjugates (2 μM) at pH 7.4 and pH 6.5. ***p < 0.001. Data are shown as mean ± SD (n=3). Scale bar = 
20 μm. 
without or with folate targeting ligand, PEG and topology as in 728 or 729 except the 
oleic acids were synthesized, analyzed, and compared for protein delivery efficiency. 
After a 45 min incubation, folate-targeted 737-SS-nlsEGFP in comparison to the 
729-SS-nlsEGFP conjugate displayed an only slightly reduced cell association (Figure 
3.11) and intracellular uptake (Figure 3.12 A) as analyzed by flow cytometry. 
However, as Figure 3.12 B reveals, after cell exposure to 729-SS-nlsEGFP for 24 h  
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Figure 3.13  Structure - intracellular protein delivery relationship of 728 and 937 (analog without oleic 
acid modification). (A) Cellular association of 728 or 937 formed nlsEGFP conjugates (1 μM) after 45 
min incubation with KB cells determined by flow cytometry. (B) Cellular internalization of 728 or 937 
formed nlsEGFP conjugates (1 μM) after 45 min incubation with KB cells determined by flow cytometry. 
(C) Relative fluorescence intensities of per cell treated with each sample for 24h, followed by another 
24 h incubation in fresh media. The intensities were normalized regarding to the mean fluorescence 
intensity of the cells treated with 937-SS-nlsEGFP. (D) Evaluation of RNase A transfection efficiency 
with 728 or 937 RNase A conjugates on KB cells by a cell metabolic activity assay (MTT assay). ***p < 
0.001. Data are shown as mean ± SD (n=3). 
under standard culture conditions, followed by another 24 h incubation in fresh media, 
the cells showed green fluorescence of nlsEGFP distributed throughout the cytosol 
and nucleus, whereas no nlsEGFP was observable in the 737-SS-nlsEGFP treated 
cells. Flow cytometry results (Figure 3.12 C) demonstrate a nine times higher 
meanfluorescence intensity for 729-SS-nlsEGFP treated cells compared with 
737-SS-nlsEGFP treated cells. An analogous comparison of the RNase A delivery 
efficiency of 729-SS-RNase A and 737-SS-RNase A gave consistent results (Figure  
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Figure 3.14  Erythrocyte leakage assay of plain oligomers (5 μM) at different pH values. (A) Leakage 
assay of 729 and 737 (analog without oleic acid modification). (B) Leakage assay of 728 and 937 
(analog without oleic acid modification). **p < 0.01, ***p < 0.001. Data are shown as mean ± SD (n=3). 
Figure 3.15  Cell viability evaluation of the cells treated with different oligomers at different 
concentration. Data are shown as mean ± SEM (n=3). 
3.12 D). KB cells treated with 729-SS-RNase A experienced significantly higher 
cytotoxicity compared with cells treated with 737-SS-RNase A. To further verify this 
conclusion, an erythrocyte leakage assay was performed to compare the lytic effects 
of 729-SS-nlsEGFP and 737-SS-nlsEGFP (Figure 3.12 E) or 729-SS-RNase A and 
737-SS-RNase A (Figure 3.12 F) on lipid membranes. A potent lytic activity was 
observed for 729-SS-nlsEGFP both at physiological pH and early endosomal pH, 
whereas, in sharp contrast, 737-SS-nlsEGFP displayed no significant hemolysis 
under these conditions (Figure 3.12 E). Similar findings were made in hemolysis  
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Figure 3.16  Metabolic cell activities (in % of untreated controls) of KB cells treated with 
729-SS-nlsEGFP or nlsEGFP-PDP at indicated concentration. Data are shown as mean ± SD (n=3). 
studies of the RNase A conjugates; again, 729-SSRNase A caused far more 
erythrocyte lysis than 737-SS-RNase A (Figure 3.12 F). These results are well 
consistent with the cell metabolic activity assays (Figure 3.12 D) after RNase A 
transductions. Also the oleic acid modified nontargeted oligomer 728 presented 
higher nlsEGFP and RNase A delivery efficiency than the control oligomer 937 (Figure 
3.13). The erythrocyte leakage assay of plain oligomers (without protein conjugation, 
Figure 3.14) also showed a higher lytic activity of the oleic acid modified oligomers 
(728, 729) than the oligomers without oleic acid (937, 737). A direct effect of the 
oligomers on cell viability however could be excluded (Figure 3.15). Furthermore, 
analogous oligomer conjugates of the nontoxic nlsEGFP protein did not mediate 
cytotoxicity (more than 80% metabolic activity of treated cells; Figure 3.16). 
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3.2 Lipo-oligomer nanoformulations for targeted intracellular protein 
delivery 
Section 3.2 has been partly adapted from: Peng Zhang, Benjamin Steinborn, Ulrich Lächelt, 
Stefan Zahler, and Ernst Wagner, Biomacromolecules DOI: 10.1021/acs.biomac.7b00666. 
In our previous research, a series of sequence-defined cationizable 
oligoaminoamides was synthesized via precise assembly of artificial amino acid 
blocks such as succinoyl tetraethylene pentamine (Stp), which presented efficient and 
effective pDNA and siRNA transfection capacities [112, 114, 116, 117]. Furthermore, 
some of these oligomers were also found to be favorable for delivery of protein into 
the cytosol of cells [120, 121, 137, 138, 144]. Especially the amphiphilic triblock 
lipo-oligomers 728 and 729 displayed high protein transduction activity ([144] and 
previous chapter), containing eight units of cationizable Stp for endosome escape, 
two terminal cysteines for reversible covalent protein conjugation and stabilizing of 
formed nanoparticles, a tetra-oleic acid block for providing hydrophobicity and 
endosomolytic activity, and a polyethylene glycol (PEG) unit for shielding optionally 
with folate (in case of 729) for targeting. For 729 protein conjugates first encouraging 
demonstration of receptor targeted delivery was obtained, the formulation however 
presented micellar protein nanorod structures (diameter 10 nm by TEM, 
hydrodynamic diameter 25-35 nm by DLS) with limited stability [144]. Therefore, aim 
of the current work has been the optimization of the formulation by combining the 
previously reported lipo-oligoaminoamide 728 – protein conjugates with various lipids, 
optionally including a novel folic acid-PEG conjugated lipid 1042 for folate receptor 
targeting. RNase A and nlsEGFP were applied as two representative cargo proteins, 
which were first coupled to 728 via disulfide bonds. These linkages are supposed to 
be reduced within the reducing cytosolic environment after the escape of conjugates 
from endolysosomes. [144, 145] We found that optimized proteoliposome 
nanoparticles including 728, DOPS, cholesterol, DMPE-PEG2000 and 1042 can 
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effectively deliver RNase A or nlsEGFP into cells in the presence of serum, where 
RNase A induces highest targeted cell killing on folate-receptor-positive KB carcinoma 
cells, and nlsEGFP undergoes highly efficient targeted delivery into the cytosol and 
nucleus of KB cells.  
3.2.1  Formation and characterization of lipo-oligomer nanoformulations  
A novel targeted intracellular protein delivery platform (Figure 3.17 A) was developed 
through the self-assembly of 728, a sequence-defined amphiphilic triblock 
oligoaminoamide lipo-oligomer, which was bioreversibly conjugated with the cargo 
protein, together with various helper lipids at defined molar ratios into proteo-lipidic 
nanoparticles. Three different helper lipids, DOPS (anionic lipid), DOPE (neutral lipid), 
LinA (fatty acid) were applied to help to form stable nanoparticles and neutralize the 
positive charges on the nanoparticle surfaces. Cholesterol was applied to stabilize 
lipid bilayers and enhance the stability of the lipidic protein nanoparticles. Three 
PEGylated lipids, DMPE-PEG2000, DSPE-PEG2000, or the novel 
folate-PEGconjugated lipid analog 1042 (see below) were also used to reduce the 
zeta potential, enhance the serum stability, and provide optional targeting capacity 
(Figure 3.18). Figure 3.17 A also displays the molar ratios of the optimized protein 
formulations and hypothetical liposomal or micellar structures depending on the 
helper lipid content (see below).  
Figure 3.19 presents the chemical structures of sequence-defined oligomers which 
were applied in the current study and generated by solid-phase synthesis [116, 117]. 
Oligomer 728 (Figure 3.19) [144] contains a monodisperse PEG chain (24 ethylene 
oxide units), coupled to the cationic backbone to decrease unspecific protein binding 
and providing a hydrophilic block. The cationizable backbone of 728 was assembled 
with a two-arm topology containing eight Stp units in total. Stp is an artificial amino 
acid building block, supposed to enhance endosomal escape of internalized 
nanomaterial by the proton-sponge effect [146]. Oleic acids were included into 728 to  
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Figure 3.17  A) Formulation components (bottom; molar ratios of optimized formulations) and 
hypothetical structures of nanoformulations (left, proteo-liposomal; right proteo-micellar, displayed for 
EGFP). B) Targeted intracellular protein delivery meditated by lipo-oligomer nanoformulations. 
provide a hydrophobic block for nanoparticle stabilization and endosomal membrane 
destabilization. Additionally, natural amino acids are integrated in 728: glutamic acid 
at the distal end of PEG; lysines serving as branching points of the two-arm topology 
via the modification of α- and ε-amino groups; cysteines for conjugation to the cargo 
proteins by reducible disulfide bonds and further crosslink-stabilization of the 
nanoformulations. The novel folate-PEG conjugated lipid analog 1042 (Figure 3.19) 
was designed as optional targeting component, with folate incorporated at the distal 
end of polyethylene glycol (containing 36 ethylene oxide units) linked with two stearic 
acids via a lysine spacer. Two cargo proteins, RNase A and nlsEGFP, were applied to  
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 Figure 3.18  Chemical structures of involved lipids. 
Figure 3.19  Chemical structure of lipo-oligomer 728 and the folic acid-PEG conjugated lipid analog 
1042. Sequences are shown from C to N terminus. Abbreviations: E: glutamic acid; OA: oleic acid; C: 
cysteine; K: branching lysine selectively modified at α and ε amines; PEG24: polyethylene glycol 
containing 24 ethylene oxide monomer units; FolA: folic acid; SteA: stearic acid; PEG36: polyethylene 
glycol containing 36 ethylene oxide monomer units. The novel FolA-PEG lipid 1042 was designed and 
synthesized by Benjamin Steinborn and Dr. Ulrich Lächelt (PhD study, Pharmaceutical Biotechnology, 
LMU Munich). 
728
1042
K- ε (PEG24-E)-K- α,ε (Stp4-C-K-OA2)2
K- ε (PEG36-FolA)-K- α,ε (SteA)2
Cholesterol
Linoleic acid
DOPS
DOPE
DMPE-PEG2000
DSPE-PEG2000
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Table 3.5  Composition (ratios in molar %) of lipo-oligomer nanoformulations. 
investigate the targeted protein delivery (Figure 3.17 B). RNase A, if internalized into 
the cytosol, can efficiently kill cancer cell through degrading the cellular RNA. [66, 
147] nlsEGFP contains a nuclear localization sequence derived from SV40 large 
T-antigen which helps to transport EGFP into the nucleus after cytosolic delivery. 
[121] To prepare the lipo-oligomer nanoformulations, RNase A (MW 13.7 kDa) or 
nlsEGFP (MW 31.5 kDa) were first covalently coupled to 728 via disulfide bonds using 
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) linkers. On average, RNase A or 
nlsEGFP molecules were modified with two or three SPDP linkers, respectively. Then, 
the PDP-modified protein was reacted with 4 (in case of RNase A) or 6 (for nlsEGFP) 
molar equivalents of 728. Subsequently, the resulting 728-SS-protein conjugates 
were added as aqueous solution to the dry lipid mixtures (various molar ratio as 
described in Table 3.5). After lyophilization and rehydration, [148, 149] as well as 
sonication, [150, 151] small and uniformly sized nanoparticles were formed. The 
nanoparticles were incubated for 48 h at room temperature, to make sure that the free 
Protein Formulation 728 
Helper 
lipids 
Cholesterol 
DM/SPE- 
PEG2000 
1042 
RNase A 
FA-728-DOPS-DMPE-RNase A 25 20 45 9.5 0.5 
FA-728-DOPE-DMPE-RNase A 25 20 45 9.5 0.5 
FA-728-LinA-DMPE-RNase A 25 20 45 9.5 0.5 
FA-728-DOPS-DSPE-RNase A 25 20 45 9.5 0.5 
FA-728-DOPE-DSPE-RNase A 25 20 45 9.5 0.5 
FA-728-LinA-DSPE-RNase A 25 20 45 9.5 0.5 
728-DOPS-DMPE-RNase A 25 20 45 10  
nlsEGFP 
FA-728-DOPS-DMPE-nlsEGFP 25 20 45 9.5 0.5 
728-DOPS-DMPE-nlsEGFP 25 20 45 10 
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Table 3.6  Particle size (Z-average) and zeta potential of protein nanoparticles in HEPES buffer 
determined by DLS. Variations refer to the median of three measurements of the same sample. 
thiols were fully oxidized via disulfide crosslinkage formation. Upon intracellular 
delivery, the disulfide bonds are supposed to be reduced in the cytosol through 
glutathione (GSH) resulting in release of oligomer-free proteins (Figure 3.17 B). The 
reversibility of conjugation between RNase A or nlsEGFP and 728 has been 
demonstrated in our previous work. [144] 
Dynamic light scattering (DLS) measurements of the prepared lipo-oligomer 
nanoformulations showed that their average sizes varied from 80 nm to 150 nm 
(Table 3.6). The zeta potential of the proteoliposomes nanoparticles varied from 6 mV 
to 22 mV (Table 3.6). The RNase A nanoparticles exhibited higher zeta potential than 
nlsEGFP nanoparticles. Helper lipid-containing nanoformulations like FA-728-DOPS- 
DMPE-RNase A and FA-728-DOPS-DMPE-nlsEGFP showed bigger particle sizes of 
~100 nm compared to the sizes ~25-35 nm of their previously described control 
conjugates 728-SS-RNase A or 728-SS-nlsEGFP without helper lipids, respectively 
(Figure 3.20 A). Meanwhile, the zeta potential was decreased from 20 mV to 13 mV 
for RNase A nanoparticles, 11 mV to 6 mV for nlsEGFP nanoparticles  
Nanoparticle Formulation Z-average(nm) PDI Zeta Potential(mV) 
FA-728-DOPS-DMPE-RNase A 111,7 ± 1,2 0,29 ± 0,00 13,6 ± 0,2 
FA-728-DOPE-DMPE-RNase A 94,6 ± 1,0 0,29 ± 0,01 18,9 ± 0,9 
FA-728-LinA-DMPE-RNase A 96,8 ± 6,1 0,45 ± 0,02 22,3 ± 2,8 
FA-728-DOPS-DSPE-RNase A 116,7 ± 0,5 0,28 ± 0,01 14,3 ± 0,6 
FA-728-DOPE-DSPE-RNase A 101,3 ± 0,5 0,42 ± 0,03 20,3 ± 1,4 
FA-728-LinA-DSPE-RNase A 154,5 ± 3,4 0,50 ± 0,01 20,5 ± 1,0 
728-DOPS-DMPE-RNase A 86,2 ± 1,5 0,39 ± 0,01 15,9 ± 0,2 
FA-728-DOPS-DMPE-nlsEGFP 119.2 ± 2.8 0.27 ± 0.01 6.09 ± 0.30 
728-DOPS-DMPE-nlsEGFP 76.9 ± 5.8 0,36 ± 0.01 8.37 ± 0.74 
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Figure 3.20 Characterization of representative lipo-oligomer nanoformulations. A) Sizes and B) Zeta 
potential of representative RNase A or nlsEGFP nanoparticles. C) Oxidation of free thiols in 
representative RNase A or nlsEGFP nanoparticles. D) Stability of representative RNase A or nlsEGFP 
nanoparticles. E) and F) TEM images of representative RNase A nanoparticles 
(FA-728-DOPS-DMPE-RNase A). Scale bar = 100 nm (E) or 50 nm (F). TEM images were generated 
by Susanne Kempter (Department of Physics, LMU Munich). 
(Figure 3.20 B). Among all tested nanoparticles, only the DOPS group presents 
relatively obvious charge decreases (Table 3.6). The oxidation of free cysteines as an 
important step in the nanoparticle formation process was also investigated using the 
Ellman’s assay. Figure 3.20 C shows that almost 100% of free thiols in 
FA-728-DOPS-DMPE-RNase A or FA-728-DOPS-DMPE-nlsEGFP nanoparticles 
were oxidized. Other tested formulations also presented almost full oxidation (Figure 
3.21). The resulting disulfide crosslinkages are supposed to stabilize the formed 
nanoparticles. Therefore, the stabilities of FA-728-DOPS-DMPE-RNase A or 
FA-728-DOPS-DMPE-nlsEGFP nanoparticles were further investigated by particle 
size measurements after 72 h. The size of the RNase A nanoparticles was unchanged 
after 72 h, and only a slight but insignificant increase was observed for nlsEGFP 
nanoparticles (Figure 3.20 D). The transmission electron microscopy (TEM) image of 
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FA-728-DOPS-DMPE-RNase A nanoparticles showed a relatively homogeneous 
distribution of round shaped nanoparticles, most of them displaying an average 
diameter of ~50 nm (Figure 3.20 E, F).  
 
Figure 3.21  Oxidation of free thiols in representative RNase A nanoparticles. Data are shown as 
mean ± SD (n=3). 
Figure 3.22  Calcein release from the RNase A nanoparticles after PBS or 3 % triton X-100 treatment. 
Statistical analysis in comparison with the PBS treated corresponding RNase A nanoparticles; ns: no 
significant difference; ***p < 0.001. Data are shown as mean ± SD (n=3). 
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Meanwhile, RNase A nanoformulations containing calcein (0.1 M) were generated by 
rehydrating the dry lipids mixtures with PBS (pH 7.4) containing 0.1 M calcein. 
Untrapped calcein was removed by size exclusion chromatography using Sephadex 
G25 column. Calcein is self-quenched at high concentration (0.1 M), [152, 153] and 
will be dequenched after release from the nanoparticles and dilution to lower 
concentrations. Calcein release studies by dissolving the formulations with triton 
X-100 resulted in calcein release and increased the fluorescence intensity in case of 
the helper lipid-containing RNase A nanoparticles but not for 728-SS-RNase A protein 
conjugate (Figure 3.22).  
 
Figure 3.23 Turbidity measurements of representative protein nanoparticles after PBS or 10% FBS 
treatment for a 2 h incubation at 37 °C. Data are shown as mean ± SD (n=3). 
Turbidity measurement results exhibited that none of the tested lipo-oligoaminoamide 
nanoparticles showed significant aggregation after PBS treatment for 2 h. After 
incubation in 10 % serum-containing buffer for 2 h, FA-728-DOPS-DMPE-RNase A 
presented highest resistance of aggregation among the RNase A nanoparticles. Also 
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the nlsEGFP nanoparticles were stable in 10% serum-containing buffer and resisted 
aggregation (Figure 3.23).  
3.2.2 Comparison of cell killing effect of lipo-oligomer RNase A 
nanoformulations 
To evaluate the protein delivery efficiency of targeted lipo-oligoaminoamide 
nanoformulations and intracellular protein bioactivity, RNase A were conjugated to the 
nanoparticles via disulfide bonds, which are supposed to increase the resistance of 
protein dissociation from nanoparticles under physiological environment. After being 
internalized into the reducing cytosol of cancer cells, the RNase A was supposed to 
be released from the nanoparticles and degrade the cellular RNA, thereby resulting in 
cancer cell killing. Folate-receptor positive KB cells were treated with the various 
RNase A nanoparticles, corresponding nanoparticles without RNase A or without 728, 
formulations of nanoparticles containing non-conjugated “free RNase A”, or RNase 
A-PDP at indicated concentration. MTT assay was used to determine the metabolic 
cell activity after 4 h incubation following another 44 h incubation in fresh medium. Cell 
treated with corresponding nanoparticles without RNase A did not show any reduction 
of metabolic activity. Also, cell viability reduction was not observed on the SPDP 
modified RNase A treated KB cells. Moreover, the cells treated with corresponding 
nanoparticles without 728 presented no cell viability reduction (Figure 3.24 A). In 
contrast, all the targeted RNase A nanoparticles showed significant cell killing. Cell 
treated with the corresponding nanoparticles containing nonconjugated “free RNase 
A” also exhibited appreciable decrease of cell viability (Figure 3.24 A). However, the 
nanoparticles conjugated with RNase A via disulfide linkage always presented higher 
cytotoxicity compared with the noncovalent formulations. Among all the tested 
targeted RNase A nanoparticles, FA-728-DOPS-DMPE-RNase A mediated the 
highest cytotoxicity, reducing the viability of KB cells down to 15%. Because of the 
promising performance on RNase A delivery, FA-728-DOPS-DMPE-RNase A was  
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Figure 3.24  A) Evaluation of RNase A transfection efficiency with various RNase A nanoparticles on 
KB cells presented as % cell metabolic activity of control cells (MTT assay). Cells were incubated with 
the indicated agents under standard culture conditions for 4 h, followed by a 44 h incubation with fresh 
media. Black: RNase A nanoparticles (2 μM); deep grey: mixtures of corresponding dose of 728, lipids 
and free RNase A (2 μM); grey: mixtures of corresponding dose of lipids and free RNase A (2 μM); light 
grey: mixtures of corresponding dose of 728 and lipids without RNase A; white: RNase A-PDP (2 μM). 
B) RNase A protein concentration-dependent cytotoxicity of FA-728-DOPS-DMPE-RNase A mediated 
transfection on folate receptor positive KB cells. Statistical analysis in comparison with the targeted 
FA-728-DOPS-DMPE-RNase A formulation; *p < 0.05, ***p < 0.001. Data are shown as mean ± SD 
(n=3). 
further investigated in more detail. Figure 3.24 B shows that the cell killing effect of 
FA-728-DOPS-DMPE-RNase A is protein concentration dependent. The 
corresponding doses of FA-728-DOPS-DMPE and RNase A-PDP show no distinct 
sign of cytotoxicity.  
Next, the targeting ability of FA-728-DOPS-DMPE-RNase A nanoparticles was 
investigated in detail. As shown in Figure 3.25 A, FA-728-DOPS-DMPE-RNase A 
presented higher folate-receptor-positive KB cell killing than 728-DOPS-DMPE- 
RNase A, and 1 mM free folic acid block could efficiently reduce the KB cell killing of 
FA-728-DOPS-DMPE-RNase A to the levels of the non-targeted control. The cell 
killing effect of FA-728-DOPS-DMPE-RNase A could also be observed on 
folate-receptor-positive L1210 cells, however, after treatment with FA-728-DOPS- 
DMPE-RNase A, the folate-receptor-negative Neuro 2A or MCF-7 cells did 
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Figure 3.25  A) Evaluation of RNase A transfection efficiency with FA-728-DOPS-DMPE-RNase A 
nanoparticles and non-targeted control 728-DOPS-DMPE-RNase A or free folic acid competition 
control on KB cells presented as % cell metabolic activity of control cells (MTT assay). Cells were 
incubated with the indicated agents under standard culture conditions for 4 h, followed by a 44 h 
incubation with fresh media. For competition experiments with free folic acid, the KB cells were 
pretreated with 1 mM free folic acid for 30 min on ice before adding nanoparticles. B) 
FA-728-DOPS-DMPE-RNase A mediated RNase A transfection on folate receptor positive L1210 cells 
in comparison to folate receptor negative cells (Neuro 2A and MCF-7). Black: RNase A nanoparticles (2 
μM); light grey: mixtures of corresponding dose of 728 and lipids without RNase A. Statistical analysis 
in comparison with the targeted FA-728-DOPS-DMPE-RNase A formulation; ***p < 0.001. Data are 
shown as mean ± SD (n=3). 
not show strong reduction of cell viability (Figure 3.25 B). Moreover, free folate block 
could also reduce KB cell killing of other five targeted RNase A nanoparticles (Figure 
3.26), which also showed effective cytotoxicity on folate-receptor-positive L1210 cells 
(Figure 3.27), but could not kill the folate-receptor-negative Neuro 2A or MCF-7 cells 
(Figure 3.28).  
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Figure 3.26  Effect of receptor competition with free folic acid on cell killing for various RNase A 
nanoparticles using MTT metabolic activity assay. KB cells were incubated with the indicated agents 
under standard culture conditions for 4 h, followed by a 44h incubation with fresh media. For 
competition experiments with free folic acid, the KB cells were pretreated with 1 mM free folic acid for 
30 min on ice before adding nanoparticles. Black: RNase A nanoparticles (2 μM); deep grey: 1 mM free 
folic acid block; light grey: corresponding nanoparticles without RNase A. Data are shown as mean ± 
SD (n=3). 
Figure 3.27  Evaluation of RNase A transfection efficiency with various RNase A nanoparticles on 
folate receptor positive L1210 cells presented as % of metabolic activity of control cells (MTT assay). 
Cells were incubated with the indicated agents under standard culture conditions for 4 h, followed by a 
44 h incubation with fresh media. Black: RNase A nanoparticles (2 μM); light grey: corresponding 
nanoparticles without RNase A. Data are shown as mean ± SD (n=3).  
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Figure 3.28  Evaluation of RNase A transfection efficiency with various RNase A nanoparticles on 
folate receptor negative Neuro 2A (A) or MCF-7 cells (B) presented as % cell metabolic activity of 
control cells (MTT assay). Cells were incubated with the indicated agents under standard culture 
conditions for 4 h, followed by a 44 h incubation with fresh media. Black: RNase A nanoparticles (2 
μM); light grey corresponding nanoparticles without RNase A. Data are shown as mean ± SD (n=3). 
The effect of co-formulation with lipids was further investigated by comparison of cell 
killing by different nanoformulations (FA-728-DOPS-DMPE-RNase A, 
728-DOPS-DMPE-RNase A, 728-SS-RNase A, FA-728-DOPS-DMPE-free RNase A 
and FA-DOPS-DMPE-RNase A) testing folate-receptor-positive KB cells in 0% FBS 
and 20% FBS containing medium. As shown in Figure 3.29 A, after KB cells were 
treated with different nanoparticles in 0% FBS containing medium for 4 h followed by  
A
B
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Figure 3.29  Influence of serum on KB cell killing efficiency mediated by various RNase A 
nanoparticles. A) Evaluation of RNase A efficacy presented as % cell metabolic activity of control KB 
cells (MTT assay). Cells were incubated with the indicated agents in serum-free medium for 4 h, 
followed by a 44 h incubation with fresh serum-containing medium. B) Evaluation of RNase A efficacy 
analogously as described in (A) but with incubation in medium containing 20% FBS for the first 4 h. 
Black: RNase A nanoparticles (2 μM); light grey: nanoparticles without RNase A. Statistical analysis in 
comparison with the targeted FA-728-DOPS-DMPE-RNase A formulation; ns: no significant difference; 
***p < 0.001. Data are shown as mean ± SD (n=3). 
another 44 h incubation in fresh 10 % FBS containing medium, FA-728-DOPS- 
DMPE-RNase A presented similar cell killing as the non-targeted control or the 
728-SS-RNase A conjugate (not significant), reducing the cellular metabolic activity of 
KB cells down to 3 %. FA-728-DOPS-DMPE-free RNase A (i.e. the formulation 
                                                                                           Results 
66 
 
containing non-conjugated RNase A) also notably decreased the metabolic activity of 
KB cells down to 10%, whereas nanoparticles without RNase A showed no 
cytotoxicity. Only KB cells treated with the plain lipo-oligomer 728 under serum-free 
conditions presented a slight 30% reduction in cellular metabolic activity. In contrast, 
when treating KB cells with the nanoformulations in 20% FBS containing medium for 4 
h, followed by another 44 h incubation in fresh 10% FBS containing medium, 
FA-728-DOPS-DMPE-RNase A presented substantial higher KB cell killing activity 
than the non-targeted formulation or 728-SS-RNase A. Also, the cytotoxicity of 
FA-728-DOPS-DMPE-free RNase A (containing nonconjugated protein) was 
dramatically reduced from 90% in 0% FBS containing medium to 40% in 20% FBS 
containing medium (Figure 3.29 B). Both in 0% FBS and 20% FBS containing serum, 
the 728-lacking control FA-DOPS-DMPE-RNase A did not present any cytotoxicity. 
3.2.3  Effective targeted intracellular delivery of nlsEGFP 
Because of the superior performance of FA-728-DOPS-DMPE-RNase A, the same 
lipid composition was also applied to prepare nlsEGFP nanoformulations. Flow 
cytometry was applied to determine the fluorescence intensity of KB cells transfected 
with nlsEGFP nanoparticles in standard 10% FCS containing medium. A 45 min short 
incubation of these folate receptor-rich cells on ice with 
FA-728-DOPS-DMPE-nlsEGFP demonstrated a higher degree of cellular association 
(Figure 3.30 A) and mean fluorescence intensity (Figure 3.30 B) than with the 
non-targeted control 728-DOPS-DMPE-nlsEGFP. A competition assay with free folate 
was also carried out to further prove the folate receptor involvement for 
FA-728-DOPS-DMPE-nlsEGFP. The free folate block could effectively inhibit the 
cellular association of FA-728-DOPS-DMPE-nlsEGFP (Figure 3.30 A) and decrease 
the mean fluorescence intensity of treated cells (Figure 3.30 B). SPDP modified 
nlsEGFP treated cells presented almost same low fluorescence intensity as the PBS 
treated cell control.  
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Figure 3.30  A) Cellular association of KB cells treated with various nlsEGFP nanoformulations (1 μM) 
on ice for 45 min by flow cytometry. For competition experiments with free folic acid, the KB cells were 
pretreated with 1 mM free folic acid for 30 min on ice before adding nanoparticles. Deep green: 
FA-728-DOPS-DMPE-nlsEGFP; light green: competition with free folic acid; orange: non-targeted 
control formulation; blue: nlsEGFP-PDP control; red: PBS treated cell control. B) Mean fluorescence 
intensities of cells treated with each sample as described in (A). ***p < 0.001. Data are shown as mean 
± SEM (n=3). 
Figure 3.31  A) Cellular internalization of cells treated with various nlsEGFP nanoparticles (1 μM) for 
24 h, followed by a 24 h incubation in fresh media. Green: FA-728-DOPS-DMPE-nlsEGFP; Orange: 
non-targeted control; Blue: nlsEGFP-PDP control; Red: PBS treated cell control. B) Mean fluorescence 
intensities of cells treated with each sample as described in (A). ***p < 0.001. Data are shown as mean 
± SEM (n=3). 
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Furthermore, the cellular internalization of nlsEGFP was also studied by incubating 
KB cells with FA-728-DOPS-DMPE-nlsEGFP or 728-DOPS-DMPE-nlsEGFP for 24 h 
at body temperature, followed by another 24 h incubation in fresh medium. The results 
showed that both formulations presented effective nlsEGFP persistence after a long 
incubation, meanwhile, FA-728-DOPS-DMPE-nlsEGFP treated cells presented more 
cell internalization of nlsEGFP and higher mean fluorescence intensity than that of 
728-DOPS-DMPE-nlsEGFP treated cells (Figure 3.31). 
 
Figure 3.32 Transduction of KB cells with various nlsEGFP nanoparticles. A) Representative 
fluorescence microscopy of the live KB cells treated with 1 μM FA-728-DOPS-DMPE-nlsEGFP (row 1), 
1 μM FA-728-DOPS-DMPE-free nlsEGFP (row 2), 1 μM FA-DOPS-DMPE-nlsEGFP (row 3) and 1 μM 
nlsEGFP-PDP (row 4) for 24 h, followed by a 24 h incubation in fresh media. Left column: bright-field 
images of the treated cells. Right column: EGFP fluorescence of the treated cells. B) Cellular 
internalization of each nanoformulation incubated as described in A) as determined by flow cytometry. 
C) Mean fluorescence intensities of cells treated with each nanoformulation. ***p < 0.001. Data are 
shown as mean ± SEM (n=3). Scale bar = 20 μm. 
A
C
B
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Figure 3.33  A) Cellular internalization of cells treated with various nlsEGFP nanoparticles (1 μM) for 
24 h, followed by a 24 h incubation in fresh media. Orange: FA-728-DOPS-DMPE-nlsEGFP; Blue: 
control conjugates without helper lipids; Red: PBS treated cell control. B) Mean fluorescence intensities 
of cells treated with each sample as described in (A). ***p < 0.001. Data are shown as mean ± SEM 
(n=3).  
Fluorescence microscopy was also used to investigate the nlsEGFP delivery 
eff iciency of FA-728-DOPS-DMPE-nlsEGFP. Figure 3.32 A shows that 
FA-728-DOPS-DMPE-nlsEGFP treated cells exhibited homogeneous green 
fluorescence all over the cells after incubation with nanoparticles for 24 h followed by 
additional incubation in fresh medium for 24 h. Furthermore, nlsEGFP was apparently 
also transported into the cell nuclei. More nlsEGFP positive cells were found in the 
fluorescence microscopy of FA-728-DOPS-DMPE-nlsEGFP treated cells compared to 
the cells treated with 728-SS-nlsEGFP as reported before, [144] which is consistent 
w i th  the  ce l lu la r  i n te rna l i za t ion  re su l t s  sho wn  in  F igu re  3 .33  A . 
FA-728-DOPS-DMPE-nlsEGFP treated cells presented also a higher mean 
fluorescence intensity than 728-SS-nlsEGFP treated cells (Figure 3.33 B). 
FA-728-DOPS-DMPE-nlsEGFP also displayed a higher cellular association compared 
with 728-SS-nlsEGFP after a 45 min short incubation on ice (Figure 3.34 A). The  
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                                                                                           Results 
70 
 
Figure 3.34  A) Cellular association of cells treated with various nlsEGFP nanoparticles (1 μM) on ice 
for 45 min. Orange: FA-728-DOPS-DMPE-nlsEGFP; Blue: control conjugates without helper lipids; 
Red: PBS treated cell control. B) Mean fluorescence intensities of cells treated with each sample as 
described in (A). ***p < 0.001. Data are shown as mean ± SEM (n=3). 
Figure 3.35  Metabolic cell activities (in % of untreated controls) of KB cells treated with 1 μM various 
nlsEGFP nanoparticles. Data are shown as mean ± SD (n=3). 
A B
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mean fluorescence intensity of FA-728-DOPS-DMPE-nlsEGFP treated cells was 
higher than that of cells treated with 728-SS-nlsEGFP in the cellular association assay 
(Figure 3.34 B). Oppositely, the SPDP modified nlsEGFP, FA-DOPS-DMPE-nlsEGFP 
(without 728) and FA-728-DOPS-DMPE-free nlsEGFP controls did not generate 
detectable nlsEGFP fluorescence in the representative fluorescence images of 
treated KB cells. Flow cytometry results further confirmed these findings. SPDP 
modified nlsEGFP and FA-DOPS-DMPE-nlsEGFP treated cells manifested the same 
fluorescence intensity as the PBS treated cell control. Cells treated with 
FA-728-DOPS-DMPE-free nlsEGFP (non-covalent protein incorporation) presented 
only slightly higher fluorescence (Figure 3.32 B). Notably, FA-728-DOPS-DMPE- 
nlsEGFP treated cells displayed a 44-fold higher mean fluorescence intensity than 
cells treated with FA-728-DOPS-DMPE-free nlsEGFP, and a 94-fold higher 
fluorescence than cells treated with FA-DOPS-DMPE-nlsEGFP (Figure 3.32 C). 
Encouragingly, none of the tested nlsEGFP nanoparticle formulations showed 
cytotoxicity (Figure 3.35). 
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4.  Discussion  
4.1  Enhanced intracellular protein transduction by sequence defined 
tetra-oleoyl oligoaminoamides targeted for cancer therapy 
Section 4.1 has been adapted from: Peng Zhang, Dongsheng He, Philipp Michael Klein, 
Xiaowen Liu, Ruth Röder, Markus Döblinger, and Ernst Wagner, Adv. Funct. Mater. 2015, 25, 
6627–6636. 
Intracellularly active proteins present a therapeutic subclass which due to delivery 
problems still is in its early stage. The particularly crucial barriers of intracellular 
protein delivery include specific delivery to the targeted cells, highly efficient cellular 
internalization, effective endolysosomal escape, timely release of proteins from the 
delivery system and following subcelluar traffic to specific subcellular sites [54, 58, 
61]. Among these barriers, especially endolysosomal entrapment hamper effective 
protein transduction into the cytosol. Cargo proteins are largely sequestrated and 
degraded in the endolysosomes without access to the subcellular target sites for 
subsequent biological actions. Therefore, novel delivery technologies are required to 
cope with these barriers via combing multiple functions. In our laboratory, using 
solid-phase synthesis technology, precise sequence-define oligomers have been 
designed and syntesiyed and contain various moieties and functions.  
In this study, from an existing library of more than 900 precise cationic 
oligoaminoamides, sixteen candidates were chosen for in-depth evaluation of 
intracellular protein delivery. All oligomers were manufactured by solid-phase 
supported synthesis to gain precise chemical structures in defined sequences and 
topologies. Folic acid was conjugated to the cationic backbone for receptor mediated 
protein transduction through a monodisperse PEG (PEG24) chain, which can help to 
reduce the unspecific interactions between nanocarriers and the biological 
environment. The backbones of different oligomers have different topologies, such as 
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two-arm, three-arm, and four-arm, [114] and consist of novel artificial amino acid 
building blocks (e.g., Stp, Sph) as basic functional units for endosomal escape. [129] 
Oleic acids were incorporated into oligomers to enhance endosomal and nanoparticle 
stabilization [114, 128]. Moreover, natural amino acids were included in these 
oligomers: lysines were included as branching points (by selective modifi cation both 
at α- and ε-amino groups), histidines [129] to promote proton sponge effect enhancing 
endolysosomal escape, tyrosines [154] and cysteines [125, 126] were coupled to 
facilitate association of conjugates by aromatic ring interactions or reducible disulfide 
bonds, respectively. Cysteines also act as bioreducible attachment sites for the cargo 
proteins. Different substitutes for folic acid (glutamic acid, glutaric acid, alanine) were 
used in the nontargeted control oligomers (Table 3.1). 
Two representative proteins, nlsEGFP and RNase A, were employed to evaluate 
targeted intracellular protein delivery. Recombinant nlsEGFP [121] contains a nuclear 
localization sequence (NLS) derived from SV40 large T-antigen which can help 
nlsEGFP in migrating from cytosol into the nucleus by natural mechanisms. Hence, 
based on this property, nlsEGFP can be utilized to characterize endolysosomal 
escape and subcellular nuclear transport by fluorescence microscopy. Meanwhile, 
RNase A [66] when internalized into the cytosol of cancer cells can degrade the 
cellular RNA and induce cell killing. Biologically reducible SPDP linkers were utilized 
to covalently attach oligomers to nlsEGFP or RNase A through disulfide bonds. 
Following endolysosomal escape, the formed disulfide linkages are supposed to be 
cleaved by cytosolic reducing glutathione (GSH). As a result, oligomer free nlsEGFP 
or RNase A will be obtained.  
SDS-PAGE results proved the successful modification of nlsEGFP and RNase A with 
representative oligomers and the modification of proteins with oligomers by disulfide 
bonds is biologically reversible at physiological conditions (Figure 3.2). The formation 
of slightly smaller and more positively charged nanoparticles by RNase A conjugates 
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compared to the nlsEGFP conjugates (Table 3.2, 3.3) may be explained by the 
intrinsic properties of RNase A (smaller, more basic protein). The discrepancy 
between TEM (10 nm, Figure 3.3) and the larger (25 nm) size of 729-SS-RNase A 
conjugates measured by DLS may be explained by the extended worm-like shape and 
because TEM was performed in vacuum state where conjugate size would shrink. 
All the nlsEGFP conjugates showed nice cellular association and internalization 
already after a short incubation. The two-arm targeted oligomer conjugates, 715 and 
729, manifested efficient folate receptor specificity. However, the four-arm oligomer 
conjugates presented lower specificity, which can be well explained by their higher 
numbers of positive charges and/or more disulfide crosslinks. The high positive 
charge can induce unspecific association on cells and more crosslinks may prevent 
folate acid arising on conjugates surface.  
Furthermore, the fluorescence intensity was investigated after a long incubation of 
cells with nlsEGFP conjugates, the fluorescence intensity was supposed to be 
reduced because of cell proliferation and/or degradation of nlsEGFP by proteases in 
lysosomes if entrapped. Only cells treated with 712, 713, 728, 729, 794 and 795 
nlsEGFP conjugates remained EGFP fluorescence-positive. Compared with 706 and 
707, respectively, 712 and 713 nlsEGFP conjugates had a higher recovery of EGFP 
fluorescence.This can be attributed to the histidines in the oligomers which have been 
reported to increase the buffer capacity, enhancing endosomal escape or postponing 
the lysosomal acidification required for protease bioactivities. These effects of 
histidines may help nlsEGFP to escape from protease degradation. 729-SS-nlsEGFP 
showed the highest percentage of fluorescence-positive cells among all the 
conjugates, which indicated that 729 may be a potent nanocarrier for targeted protein 
delivery. 
Fluorescence microscopy was performed to confirm the capacity of these oligomers to 
deliver nlsEGFP into cells, promote endolysosomal escape, and subsequent 
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subcellular trafficking into the nucleus. 729-SS-nlsEGFP and 728-SS-nlsEGFP 
treated cells presented homogeneous fluorescence throughout the cells. This 
suggests that 729-SS-nlsEGFP and 728-SS-nlsEGFP successfully escaped from 
endosomes/lysosomes and were reduced in the cytosol, resulting in oligomer-free 
nlsEGFP all over the cells. Moreover, nlsEGFP was found imported into the cell 
nuclei, compared with only cytosolic location (presented by dark appearance of the 
nuclei) as observed in previous work [121], which also validates the successful 
endosomal escape of 729-SS-nlsEGFP and 728-SS-nlsEGFP, the biological 
reversibility of conjugation, and subsequent nuclear translocation mediated via the 
NLS signal. The nlsEGFP was not concentrated in the nucleus, which may result from 
incomplete release of nlsEGFP from the carrier or linker, as the NLS 
(Pro-Lys-Lys-Lys-Arg-Lys-Val) of nlsEGFP is rich in lysines, it is quite possible that 
some NLS lysines are irreversibly amidated by the SPDP linker. Such modified NLS 
would not work as a nuclear localization signal.  
The performances of the targeted FolA containing 729 conjugate and the nontargeted 
glutamate-containing 728 conjugate can be directly compared by microscopy and flow 
cytometry. FolA-targeted 729-SSnlsEGFP shows more efficient and effective 
nlsEGFP transduction ability as compared to the nontargeted 728-SS-nlsEGFP. 
Covalent conjugation by disulfide bonds plays a decisive role in the nlsEGFP 
transfection, which was demonstrated by the ineffectiveness of the mixtures of 729 
and free nlsEGFP. 729-SS-nlsEGFP is the only conjugate presenting nice cellular 
association, cellular internalization, folate receptor specificity, long-term survival of 
nlsEGFP activity, and subcellular nuclear import among all the targeted oligomers. 
The protein delivery efficiency of oligomers was further compared through conjugating 
oligomers with RNase A as therapeutic cargo protein. Successful delivery of RNase A 
into the cytosol was expected to elicit degradation of cytosolic RNA, thereby inducing 
cell killing. Five targeted oligomers (707, 713, 729, 733, 795) and their nontargeted 
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control oligomers could successfully induce tumor cell killing but the plain oligomers 
did not induce significant tumor cell killing. The corresponding dose of SPDP linker 
modified RNase A did also not result in any detectable change of cell viability, which 
can be attributed to the lack of intracellular delivery for SPDP modified RNase A. Cells 
treated with the mixtures of free RNase A and oligomers also presented appreciable 
reduction of metabolic activity. Such an effect of noncovalent mixtures was not 
observed in the nlsEGFP delivery (Figure 3.7 A) and is presumably based on the 
special properties of RNase A. The intrinsic positive charge of RNase A (pI 9.6) 
enables the protein to bind to the negatively charged cell membrane; simultaneous 
internalization of membrane-bound RNase A with the endosomolytic oligomers, as a 
result, may indirectly mediate endosomal release into the cytosol, analogously as 
observed elsewhere [155]. Among all the tested conjugates, 729-SS-RNase A (Figure 
3.8 A) and its nontargeted 728 analog (Figure 3.9) mediated the by far highest 
cytotoxicity, whereas the toxicity of the free oligomer was negligible. 
Interestingly, no significant decrease in cell viability was observed in 
folate-receptor-negative cells (MCF-7 and Neuro-2a) after incubation with 
729-SSRNase A conjugate at the same concentrations. It remains to be determined 
whether the major reasons are (i) reduced cellular uptake due to lack of target 
receptor or (ii) reduced sensitivity toward internalized RNase A, for example by 
different levels of natural cytosolic ribonuclease inhibitor [66], the main physiological 
inhibitor of RNase A. In our previous siRNA delivery work, gene silencing was less 
challenging in Neuro-2a cells than in KB cells [128, 156, 157], arguing against 
alternative (i) as exclusive reason. Preference of RNase in killing a series of tumor 
cells as opposed to normal cells has been reported in the literature, with reasons 
which go beyond delivery and are still not fully understood [65, 66]. The higher cell 
internalization efficiency of 729-SS-RNase A-FITC than free RNase A-FITC-PDP was 
also confirmed by fluorescence microscopy and flow cytometry evalution, revealing 
again that 729 is a potent nanocarrier for protein delivery (Figure 3.10). 
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The key role of oleic acids in oligomer 729 was investigated by compared the protein 
delivery efficiency of 728 or 729 with their control oligomers (937, 737). The control 
oligomers have the same sequence, functional modules and topology as in 728 or 729 
except the oleic acids. Flow cytometry results suggest that the oleic acids do not have 
a significantly enhancing effect on cellular binding or uptake of nlsEGFP conjugates 
(Figure 3.11, 3.12 A). However, after a long incubation, the 729-SS-nlsEGFP treated 
cells showed green fluorescence of nlsEGFP distributed throughout the cytosol and 
nucleus, whereas no nlsEGFP was observable in the 737-SS-nlsEGFP treated cells, 
which is consistent with the flow cytometry results (Figure 3.12 B, C), indicating that 
the proteins had been degraded by lysosomal proteases because of endolysosomal 
entrapment. Considering the similar molecular structure and cell uptake ability of 
729-SSnlsEGFP and 737-SS-nlsEGFP, we concluded that the different protein 
delivery efficiency may result from the distinct endosomal escape efficacy based on 
the oleic acid modification. An analogous comparison of the RNase A delivery 
efficiency of 729-SS-RNase A and 737-SS-RNase A gave consistent results. Also the 
oleic acid modified nontargeted oligomer 728 presented higher nlsEGFP and RNase 
A delivery efficiency than the control oligomer 937. The far more erythrocyte lysis of 
oleic acid modified oligomers (728, 729) or their protein conjugates further verified this 
conclusion when compared with the oligomers without oleic acid (937, 737) or their 
protein conjugates, respectively. All these results proved that the oleic acids as the 
endosomolytic unit in 729 play a crucial role in the enhanced intracellular protein 
delivery. 
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4.2  Lipo-oligomer nanoformulations for targeted intracellular protein 
delivery 
Section 4.2 has been partly adapted from: Peng Zhang, Benjamin Steinborn, Ulrich Lächelt, 
Stefan Zahler, and Ernst Wagner, Biomacromolecules DOI: 10.1021/acs.biomac.7b00666. 
In this study, novel lipo-oligoaminoamide nanoformulations for targeted intracellular 
protein delivery are generated by first bioreversibly conjugating a sequence-defined 
amphiphilic lipo-oligomer 728 to the cargo protein via disulfide bonds, followed by 
formulation of the formed 728-SS-protein conjugate with different helper lipids in 
various compositions. The triblock oligoaminoamide 728 contains cysteines for 
reversible covalent protein conjugation and crosslink-stabilization of formed 
nanoparticles, polyethylene glycol (PEG) for shielding and providing a hydrophilic 
domain, eight cationizable succinoyl tetraethylene pentamine (Stp) repeats for 
endosomal buffering and escape into the cytosol, and a tetra-oleic acid block for 
hydrophobic stabilization. Three different helper lipids, DOPS (anionic lipid), DOPE 
(neutral lipid), LinA (fatty acid) were applied to help to form stable nanoparticles and 
neutralize the positive charges on the nanoparticle surfaces. Cholesterol was applied 
to stabilize lipid bilayers and enhance the stability of the lipidic protein nanoparticles. 
Three PEGylated lipids, DMPE-PEG2000, DSPE-PEG2000, or the novel 
folate-PEGconjugated lipid analog 1042 were also used to reduce the zeta potential, 
enhance the serum stability, and provide optional targeting capacity. 
Dynamic light scattering (DLS) measurements showed that the prepared lipo-oligomer 
nanoformulations had nanoscale sizes varied from 80 nm to 150 nm. The zeta 
potential of the proteoliposomes nanoparticles varied from 6 mV to 22 mV, strongly 
depending on the intrinsic properties of proteins (Table 3.6). The RNase A 
nanoparticles exhibited higher zeta potential than nlsEGFP nanoparticles, this may be 
attributed to the positive charges of RNase A (a basic protein) at pH 7.4. This also 
indicated that the covalently attached proteins are at least partly exposed at the 
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outside surface of nanoparticles. The difference of size and zeta potential between 
representative lipid-based nanoparticles and nanoparticles formed from lipo-oligomer 
protein conjugates is clear and validate the effective co-formulations of 728 
conjugates with helper lipids (Figure 3.20 A, B). Among all tested nanoparticles, only 
the DOPS group presents relatively obvious charge decreases, which can be 
attributed to the negative charge of DOPS (Table 3.6). All the tested formulations 
presented almost full oxidation of free cysteines. The resulting disulfide crosslinkages 
are supposed to stabilize the formed nanoparticles. The representative 
FA-728-DOPS-DMPE-RNase A or FA-728-DOPS-DMPE-nlsEGFP nanoparticles 
exhibited high stability in 72h (Figure 3.20 D). The size difference of the 
representative RNase A nanoparticles between DLS and TEM measurements are 
supposed to derive from the shrink effect of nanoparticles under vacuum state in TEM 
and the over-emphasized scattering intensity of larger nanoparticles in the DLS 
measurements. 
Hypothetical structures for the protein-containing nanoformulations (namely liposomal 
or micellar structures) are outlined (Figure 3.17 A). For 728-SS-protein conjugates 
without helper lipids, lipid bilayer structures as occurring in liposomes can be excluded 
based on theoretical considerations [158-162]; for example, 6 molar equivalents of 
728 (i.e. 24 equivalents of oleic acids, ~4 nm2 of bilayer) cannot provide sufficient 
lipidic membrane area compared with the EGFP protein area (~4.5-10 nm2) [163] for 
bilayer formation; only worm-like micellar structures, consistent with reported TEM 
results [144], can be formed. The situation should be different with the added helper 
lipids; according to the applied molar ratio, the approximately 30 lipid equivalents 
would be sufficient to support one EGFP molecule. In fact, 15 lipids can supply 
enough area (~10 nm2) [158-162] for one attached EGFP molecule (~4.5-10 nm2) 
[163], suggesting that liposomal bilayer formation is possible. For that case, 
proteo-liposomal nanostructures are expected to contain an inner aqueous core, 
                                                                                      Discussion                                                                                                                              
80 
 
which was validated by the increased fluorescence in the calclein release assay 
(Figure 3.22).  
In the comparison of cell killing effect of lipo-oligomer RNase A nanoformulations, cell 
viability reduction was not observed on the SPDP modified RNase A treated KB cells, 
which may derive from the lack of effective delivery of SPDP modified RNase A into 
cytosol. Moreover, the cells treated with corresponding nanoparticles without 728 
presented no cell viability reduction (Figure 3.24 A). This result may derive from the 
lack of strong association between RNase A and lipid nanoparticles, and the lack of 
efficient endolysosomal escape, whereas 728 is supposed to provide both functions. 
In contrast, all the targeted RNase A nanoparticles showed significant cell killing, 
validating efficient intracellular RNase A delivery and bioactivity. Cell treated with the 
corresponding nanoparticles containing nonconjugated “free RNase A” also exhibited 
appreciable decrease of cell viability (Figure 3.24 A). This effect may also be 
attributed to intrinsic property of the RNase A. RNase A (pI 9.6) as a basic protein with 
positive charge under physiological conditions may bind to the cell membrane and 
internalize simultaneously with nanoparticles of FA-728-DOPS-DMPE, resulting in 
indirect endolysosomal escape. However, the nanoparticles conjugated with RNase A 
via disulfide linkage always presented higher cytotoxicity compared with the 
noncovalent formulations, which may result from the increased protein loading 
efficiency upon covalent attachment and the higher resistance against dissociation 
between proteins and nanoparticles under serum containing conditions. Among all the 
tested targeted RNase A nanoparticles, FA-728-DOPS-DMPE-RNase A mediated the 
highest cytotoxicity. This effect may be attributed to relatively higher serum stability, 
as shown in the turbidity assay (Figure 3.23). Among the tested targeted RNase A 
nanoparticles, FA-728-DOPS-DMPE-RNase A showed highest resistance against 
aggregation. The relatively low zeta potential of FA-728-DOPS-DMPE-RNase A may 
contribute to this. The cytotoxicity of FA-728-DOPS-DMPE-RNase A is RNase A 
protein concentration-dependent. FA-728-DOPS-DMPE-RNase A also presented 
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effective targeting ability as proved by the higher folate-receptor-positive KB cells 
killing than the non-targeted control and free folic acid competiton control, as well as 
the effective killing of folate-receptor-positive L1210 cells but without killing the 
folate-receptor-negative cells Neuro 2A or MCF-7. 
FA-728-DOPS-DMPE-RNase A presented similar cell killing as the non-targeted 
control or the 728-SS-RNase A conjugate (not significant) after incubation in 0% FBS 
containing medium, but presented substantial higher KB cell killing activity than the 
non-targeted formulation or 728-SS-RNase A after treating KB cells with the 
nanoformulations in 20% FBS containing medium, which may result from the targeting 
ability of FA-728-DOPS-DMPE-RNase A and higher serum stability compared with 
728-SS-RNase A (Figure 3.23). Also, the dramatic reduction of cytotoxicity of 
FA-728-DOPS-DMPE-free RNase A (containing nonconjugated protein) from 0% FBS 
containing medium treatment to 20% FBS containing medium treatment (Figure 3.29) 
validates the importance of covalent attachment to enhance serum stability. Both in 
0% FBS and 20% FBS containing serum, the 728-lacking control 
FA-DOPS-DMPE-RNase A did not present any cytotoxicity, which further proves the 
key role of 728 in the lipo-oligomer nanoformulation. 
Furthermore, using nlsEGFP as cargo protein, FA-728-DOPS-DMPE-nlsEGFP 
presented higher cellular association and cellular internalization, as well as higher 
mean fluorescence intensity than the non-targeted control 
728-DOPS-DMPE-nlsEGFP, evidencing the targeting nlsEGFP delivery ability of 
FA-728-DOPS-DMPE-nlsEGFP nanoparticles. Both formulations presented effective 
nlsEGFP persistence after a long incubation, validating efficient resistance to 
protease degradation if entrapped in lysosomes.  
FA-728-DOPS-DMPE-nlsEGFP treated cells exhibited homogeneous green 
fluorescence all over the cells under fluorescence microscopy. This presented that 
FA-728-DOPS-DMPE-nlsEGFP underwent successful endolysosomal escape and 
                                                                                      Discussion                                                                                                                              
82 
 
nlsEGFP was released from the nanoparticles in the reducible cytosolic environment, 
resulting in oligomer-free nlsEGFP throughout the cells. Furthermore, nlsEGFP was 
apparently also transported into the cell nuclei, which further validated the effective 
endolysosomal escape of FA-728-DOPS-DMPE-nlsEGFP, the bioreversibility of 
disulfide linkage, and the following nuclear localization of nlsEGFP via the NLS 
sequence. More nlsEGFP positive cells were found in the fluorescence microscopy of 
FA-728-DOPS-DMPE-nlsEGFP treated cells compared to the cells treated with 
728-SS-nlsEGFP as reported before [144], which is consistent with the cellular 
internalization and mean fluorescence intensity results shown in Figure 3.33. These 
results proved that introduction of helper lipids significantly enhanced the targeted 
intracellular transduction of nlsEGFP. The ineffectiveness of 
FA-DOPS-DMPE-nlsEGFP and FA-728-DOPS-DMPE-free nlsEGFP further proved 
that 728 and bioreversible covalent attachment of GFP via disulfide linkages play a 
crucial role in the intracellular protein delivery. These results are consistent with 
corresponding RNase A transfection results (Figure 3.24). 
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5.  Summary 
Protein therapeutics present great potency in the treatment of various diseases 
because of their higher functional specificity and less adverse effects over 
small-molecule drugs. Since the introduction of human insulin as the first recombinant 
protein therapeutic in 1982, numerous protein therapeutics have been developed and 
widely applied in disease therapy, such as diabetes, hepatitis, haemophilia, and 
malignant tumors. However, clinically applied protein therapeutics are largely limited 
to those exerting their bioactivity extracellularly. Protein biologics which perform 
functions in the cytosol have not been widely applied in clinical trials due to the lack of 
efficient intracellular delivery technology. The particular crucial barriers include 
specific delivery to the targeted cells, highly efficient cellular internalization, effective 
endolysosomal escape, timely release of proteins from the delivery system and 
following subcelluar traffic to specific subcellular sites. Among these barriers, 
especially endolysosomal entrapment hamper effective protein transduction into the 
cytosol. Cargo proteins are largely sequestrated and degraded in the endolysosomes 
without access to the subcellular target sites for subsequent biological actions. 
Therefore, novel delivery technologies are required to cope with these barriers via 
combing multiple functions. Precise sequence-define oligomers have been designed 
and syntesiyed and contain various moieties and functions in our laboratory using 
solid-phase synthesis technology. Here, the thesis further expanded the application of 
sequence-define oligomers for targeted intracellular protein transduction and cancer 
therapy with effective endosomal escape and further improved the efficiency and 
stability of targeted intracellular protein delivery nanoformulations through 
incorporation of lipids. 
In the first part, based on our former work, which established a library of more than 
900 precise sequence-defined oligoaminoamide oligomers, we further expand their 
application for targeted intracellular protein transduction and cancer therapy. 
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Screening a small library of selected candidates, we identified sequence defined 
oligomers comprising PEG as hydrophilic shielding agent and optionally folic acid as 
targeting ligand as potent intracellular transduction agents for proteins covalently 
conjugated via bioreversible disulfide bonds. All evaluated oligomers present 
encouraging cellular association and internalization of protein as evidenced by 
nlsEGFP delivery. However, only the two-arm oligomers which were terminally 
modified with oleic acids showed both efficient cytosolic and nuclear delivery, and 
intracellular persistence of nlsEGFP. The oleic acid modification was a molecular 
requirement in conjugates for nanoparticle formation with medium small size of 25–35 
nm, for destabilizing target lipid membranes enhancing cytosolic delivery, and 
altogether for efficient protein transduction. Folate-containing receptor targeted 
oligomer conjugates presented superior nlsEGFP transfection efficiency over the 
nontargeted control oligomer conjugates. Furthermore, choosing RNase A as a cargo 
protein for cancer therapy, the oleic acid modified two-arm oligomers again showed 
the most significant antitumoral effect. These results demonstrate the oleic acid 
modified sequence defined oligoaminoamide oligomers as a novel and promising 
nanocarrier for targeted intracellular protein delivery and cancer therapy. 
In the second part, a novel targeted intracellular protein delivery system was 
developed by bioreversible coupling of cargo protein with the sequence defined 
amphiphilic triblock lipo-oligoaminoamide 728 followed by self-assembly with a variety 
of helper lipids (DOPS; DOPE; or linoleic acid), cholesterol, PEGylated lipids 
(DMPE-PEG2000 or DSPE-PEG2000) and optionally a folic acid-PEG conjugated 
lipid analog 1042 for targeting. Protein cargos RNase A or nlsEGFP were covalently 
coupled to lipo-oligomer 728 via disulfide linkages before nanoformulation. The 
disulfide bonds are supposed to be reduced in the cytosol after cellular uptake and 
endosomal escape, resulting in the release of oligomer-free proteins. Optimized 
protein nanoparticles including 728, DOPS, cholesterol, DMPE-PEG2000 and 1042 
presented particle sizes of ~100 nm by DLS and ~50 nm by TEM, and a decreased 
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zeta potential compared to the control conjugates without helper lipids. They display a 
high colloidal stability in various conditions including high serum-containing medium, 
and mediated improved targeted cytosolic delivery of RNase A and nlsEGFP 
compared with the 728-SS-protein conjugates, resulting in the highest RNase 
A-induced cell killing on folate-receptor-positive KB cells, effective cell killing even 
under higher serum conditions, and effective delivery of nlsEGFP into the nucleus. In 
sum, the bioreversible lipo-oligomer protein conjugation combined with helper lipid 
nanoformulation presents a promising platform for intracellular protein delivery. 
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6.  Abbreviations 
 
ACN  Acetonitrile  
BCA Bicinchoninic acid assay 
Boc  tert-Butoxycarbonyl  
BSA Bovine serum albumin 
CPP Cell-penetrating peptide 
D2O  Deuterium oxide  
DAPI  4',6-Diamidino-2-phenylindole  
DCM  Dichloromethane  
Dde  1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl  
DIPEA  N,N-Diisopropylethylamine  
DLS  Dynamic laser-light scattering  
DMEM  Dulbecco’s modified Eagle’s medium  
DMF  N,N-Dimethylformamide  
DMSO  Dimethylsulfoxide  
DODT  3,6-Dioxa-1,8-octanedithiol  
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOPS 1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
DMPE-PEG2000 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[metho
xy(polyethylene glycol)-2000] 
DSPE-PEG2000 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methox
y(polyethylene glycol)-2000]  
DTNB  5,5’-Dithio-bis(2-nitrobenzoic acid)  
DTT DL-Dithiothreitol 
EDTA  Ethylendiaminetetraacetic acid  
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EGFP Enhanced green fluorescent protein 
FBS  Fetal bovine serum  
FDA Food and Drug Administration 
FITC Fluorescein isothiocyanate 
Fmoc  Fluorenylmethoxycarbonyl  
FolA  Folic acid  
FR  Folate receptor  
HCl  Hydrochloric acid  
HEPES  N-(2-hydroxethyl) piperazine-N‘-(2-ethansulfonic acid)  
HIV Human immunodeficiency virus 
HOBt  1-Hydroxybenzotriazole  
IPTG Isopropyl β-D-1-thiogalactopyranoside 
KCN  Potassium cyanide  
LinA Linoleic acid 
MTBE  Methyl tert-butyl ether  
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
MWCO Molecular Weight Cut Off 
NaOH  Sodium hydroxide  
NLS Nuclear localization signal 
nlsEGFP Nuclear localization signal tagged EGFP 
NMR  Nuclear magnetic resonance  
OleA Oleic acid 
PBS  Phosphate buffered saline  
PDI  Polydispersity index  
                                                                                   Abbreviations                                                                                                                                                                                     
88 
 
PEG  Polyethylene glycol  
PyBOP  Benzotriazol-1-yloxy-tripyrrolidinophosphonium 
hexafluorophosphate  
RP-HPLC  Reversed-phase high performance liquid chromatography  
RPMI  Roswell Park Memorial Institute medium  
RNA Ribonucleic acid 
RNase A Ribonuclease A 
RT  Room temperature  
SEC  Size-exclusion chromatography  
SPDP N-succinimidyl 3-(2-pyridyldithio) propionate 
Sph  Succinoyl-pentaethylene hexamine  
SPS  Solid-phase synthesis  
Stp  Succinoyl-tetraethylene pentamine  
TEPA  Tetraethylene pentamine  
TEM  Transmission electron microscopy  
TFA  Trifluoroacetic acid  
TIS  Triisopropylsilane  
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